



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims EN 15, 26

(51) Int Cl.:
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 25/00 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 43/00 ^(2006.01) **C12N 15/13** ^(2006.01)

(48) Corrigendum issued on:
19.02.2014 Bulletin 2014/08

(86) International application number:
PCT/EP2009/051285

(45) Date of publication and mention
of the grant of the patent:
14.08.2013 Bulletin 2013/33

(87) International publication number:
WO 2009/098238 (13.08.2009 Gazette 2009/33)

(21) Application number: **09708019.6**

(22) Date of filing: **04.02.2009**

(54) **ANTI-TRKA ANTIBODIES AND DERIVATIVES THEREOF**

ANTI-TRKA-ANTIKÖRPER UND IHRE DERIVATE

ANTICORPS ANTI-TRKA ET LEURS DÉRIVÉS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**

(30) Priority: **04.02.2008 US 25995 P**

(43) Date of publication of application:
24.11.2010 Bulletin 2010/47

(73) Proprietor: **Lay Line Genomics S.P.A.**
00152 Rome (IT)

(72) Inventors:
• **BENIGNI, Fabio**
00152 Roma (IT)
• **D'AMBROSIO, Daniele**
00152 Roma (IT)

(74) Representative: **Schöllhorn, Andreas et al**
Latscha Schöllhorn Partner AG
Aeschenvorstadt 55
4051 Basel (CH)

(56) References cited:
WO-A-00/73344 WO-A-2005/061540
WO-A-2006/131951 WO-A-2006/137106

- **UGOLINI GABRIELE ET AL:** "The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain." **PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA** 20 FEB 2007, vol. 104, no. 8, 20 February 2007 (2007-02-20), pages 2985-2990, XP002523974 ISSN: 0027-8424
- **CATTANEO A ET AL:** "FUNCTIONAL BLOCKADE OF TYROSINE KINASE A IN THE RAT BASAL FOREBRAIN BY A NOVEL ANTAGONISTIC ANTI-RECEPTOR MONOCLONAL ANTIBODY" **JOURNAL OF NEUROSCIENCE**, NEW YORK, NY, US, vol. 19, no. 22, 15 November 1999 (1999-11-15), pages 9687-9697, XP000945020 ISSN: 0270-6474
- **ANAND P ET AL:** "The role of endogenous nerve growth factor in human diabetic neuropathy.", **NATURE MEDICINE** JUN 1996 LNKD- PUBMED: 8640566, vol. 2, no. 6, June 1996 (1996-06), pages 703-707, ISSN: 1078-8956
- **KRAMER K ET AL:** "Monoclonal antibody to human Trk-A: Diagnostic and therapeutic potential in neuroblastoma", **EUROPEAN JOURNAL OF CANCER**, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 12, 1 October 1997 (1997-10-01), pages 2090-2091, XP002139706, ISSN: 0959-8049, DOI: DOI:10.1016/S0959-8049(97)00210-4

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- LINDSAY R M ET AL: "Neurotrophic factors: from molecule to man", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 5, 1 January 1994 (1994-01-01), pages 182-190, XP024352366, ISSN: 0166-2236, DOI: DOI: 10.1016/0166-2236(94)90099-X [retrieved on 1994-01-01]

Description

[0001] The present invention relates to antibodies and to derivatives thereof, especially to humanised antibodies and derivatives thereof.

[0002] Nerve growth factor (NGF) acts through two membrane receptors. One is the relatively low affinity p75 receptor. The other is a 140 KDa high affinity receptor, known as TrkA.

[0003] NGF has potential use in the treatment of a wide range of disorders, such as various neurodegenerative disorders (including Alzheimer's disease), diabetes and leprosy.

[0004] However NGF can have various undesired agonist properties. These include an increase in pain sensitivity. The NGF-TrkA system provides a potential target for therapies for pain.

[0005] Various anti-TrkA antibodies have been produced. One such antibody is a monoclonal antibody which is referred to as 5C3 in WO 97/21732 (McGill University). However, this was found to be a TrkA agonist and is therefore not useful for reducing pain. Specifically, when binding to TrkA this antibody does not prevent the functional activation thereof.

[0006] An anti-TrkA monoclonal antibody known as MNAC13 is disclosed in WO 00/73344 (Societa Italiana Per La Ricerca Scientifica), from which EP-B-118138 (Lay Line Genomics SpA) is derived. This antibody and various derivatives thereof are said to be effective in preventing the functional activation of TrkA in a range of biological systems. The MNAC 13 monoclonal antibody was used in a standard nociception test and was found to provide remarkable hypoalgesia.

[0007] A single chain Fv (ScFv) variant of this antibody is also disclosed in WO 00/73344 and is referred to therein as MNAC13 ScFv. This contains the variable light and heavy chain regions of the larger antibody linked together by a linker polypeptide, which joins the C-terminus of the VL region with the N-terminus of the VH region. This variant was found to bind TrkA as efficiently as MNAC 13. The sequence of the light and heavy variable regions was compared with that of the corresponding regions of the antibody described in

[0008] WO 97/21732 and it was found that there was only a low level of overall sequence identity therewith.

[0009] WO 06/131952 (Lay Line Genomics SpA) discloses medical uses of anti-TrkA antibodies in treating chronic pain. It provides evidence of this by using models of persistent pain, in particular the Chronic Constriction Injury (CCI) model.

[0010] WO 06/137106 (Lay Line Genomics SpA) discloses using an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA in combination with at least one opioid analgesic for treating or preventing pain. It is explained that this combination therapy allows a reduced opioid dosage to provide the same level of pain relief as a much higher dosage. This can therefore be useful in reducing the level of opioid side effects in pain therapy, because dosages can be lowered.

[0011] WO 05/061540 (Lay Line Genomics SpA & Scuola Internazionale Superiore Di Studi Avanzati-Sissa) discloses a method of humanisation of antibodies in which structural data obtained from crystallographic studies are used to conduct the first design stages of humanisation. As examples, WO 05/061540 takes anti-TrkA antibodies, as disclosed in WO 00/73344, and anti-NGF antibodies as starting points, and then redesigns them using the disclosed method.

[0012] Whilst the humanised antibodies disclosed in WO 05/061540 are useful, there is a need to provide additional humanised antibodies so as to expand the possibilities for effective therapies.

[0013] The present inventors have now provided a range of anti-TrkA antibodies and derivatives thereof that are not disclosed in WO 05/061540. The inventors have also provided data indicating the utility of such antibodies. Prior to the present invention these antibodies were simply not known in the art and the data provided could not have been predicted.

[0014] According to one aspect of the present disclosure there is provided an anti-TrkA antibody that comprises:

a) a variable heavy chain comprising a sequence selected from any of BXhVH1 (SEQ ID NO 1), BXhVH2 (SEQ ID NO 2), BXhVH3 (SEQ ID NO 3), BXhVH4 (SEQ ID NO 4), BXhVH5 (SEQ ID NO 5), or HuVHWov (SEQ ID NO 6), as shown in Figure 1a; or from variants of any of said sequences; and/or

b) a variable light chain comprising a sequence selected from any of BXhVL1 (SEQ ID NO 7), BXhVL2 (SEQ ID NO 8), BXhVL3 (SEQ ID NO 9), BXhVL4 (SEQ ID NO 10), BXhVL5 (SEQ ID NO 11), BXhVL6 (SEQ ID NO 12), BXhVL7 (SEQ ID NO 13) or BXhVL8 (SEQ ID NO 14); as shown in Figure 1b, or from variants of any of said sequences.

[0015] A derivative of said antibody is also provided; wherein the derivative is capable of binding TrkA.

[0016] More preferably, the antibody comprises both a variable heavy chain as described in a) above and a variable light chain as described in part b), i.e. it comprises one of the following combinations of light and heavy chains:

BXhVH1VL1, BXhVH1VL2, BXhVH1VL3, BXhVH1VL4, BXhVH1VL5, BXhVH1VL6, BXhVH1VL7, BXhVH1VL8,

BXhVH2VL1, BXhVH2VL2, BXhVH2VL3, BXhVH2VL4, BXhVH2VL5, BXhVH2VL6, BXhVH2VL7, BXhVH2VL8,

BXhVH3VL1, BXhVH3VL2, BXhVH3VL3, BXhVH3VL4, BXhVH3VL5, BXhVH3VL6, BXhVH3VL7, BXhVH3VL8,
 BXhVH4VL1, BXhVH4VL2, BXhVH4VL3, BXhVH4VL4, BXhVH4VL5, BXhVH4VL6, BXhVH4VL7, BXhVH4VL8,
 5 BXhVH5VL1, BXhVH5VL2, BXhVH5VL3, BXhVH5VL4, BXhVH5VL5, BXhVH5VL6, BXhVH5VL7, BXhVH5VL8,

or HuVHWOv/HuVLWO.

[0017] Desirably, the derivative of the antibody has at least one CDR region selected from the regions underlined in Figures 1a & 1b for each sequence, or from variants thereof having no more than two amino acid changes (preferably no more than one amino acid change) per underlined region.

[0018] More desirably, it has a plurality of CDR regions selected from the regions underlined in Figures 1a & 1b for each sequence, or from variants thereof having no more than two amino acid changes (preferably no more than one amino acid change) per underlined region.

[0019] It may therefore comprise one, two, three, four, five or six of such CDR regions (optionally in combination with one or more other CDR regions).

It may preferably comprise at least the third CDR region of the heavy chain, more preferably at least the third CDR region of the heavy and light chains.

[0020] Most desirably, however, it has six CDR regions corresponding to the six CDR regions underlined in Figures 1a & 1b for each sequence or corresponding to variants thereof having no more than two amino acid changes per underlined region.

[0021] Indeed, in most cases, it is preferred that few or no changes are made to the CDR sequences. Thus one, two, three, four, five, or even all six CDR regions may have the same amino acid sequences as those shown in Figures 1a & 1b.

[0022] Turning now to framework regions, it is preferred that the derivative has at least one framework region selected from the non-underlined sequences shown in Figures 1a & 1b or from variants thereof that have at least 75% amino acid sequence identity therewith (e.g. at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity therewith).

[0023] The degree of amino acid sequence identity can be determined by simple alignments of the sequences without any gaps and determining the sequence differences.

[0024] Sequences can be aligned according to Kabat's numbering scheme and sequence identities can then be determined accordingly (See Kabat, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda MD, 1987 & 1991). This numbering scheme is discussed in WO 05/061540 (Reference can also be made to Chothia & Lesk, J. Mol. Biol., 196, 901 (1987) and to Chothia et al., Nature, 342, 878 (1989)).

[0025] Less preferably, one or more gaps may be allowed (e.g. for one or more amino acid insertions/deletions) and gap penalties may then be assigned.

[0026] Sequence identity can be determined using sequence analysis software e. g., BLASTN or BLASTP (available at www.ncbi.nlm.nih.gov/BLAST/). The default parameters for comparing two sequences (e.g. "Blast"ing two sequences against each other) by BLASTN (for nucleotide sequences) are reward for match = 1, penalty for mismatch = 2, open gap = 5,

extension gap = 2. When using BLASTP for protein sequences, the default parameters are reward for match = 0, penalty for mismatch = 0, open gap = 11, and extension gap = 1].

[0027] More preferably, a plurality of framework regions is present and these regions are selected from the non-underlined sequences shown in Figure 1a & 1b or from variants thereof that have at least 75% amino acid sequence identity therewith (e.g. at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity).

[0028] Each chain shown in Figure 1a & 1b has four framework regions. Thus it is preferred that at least two, at least three or four such regions/variants thereof are present.

[0029] Most preferably, all four framework regions or variants thereof are present.

[0030] Where one or more variant framework regions are present, it is generally preferred that these regions do not include amino acid substitutions that would result in a change to an amino acid that is present in a murine sequence at the corresponding position.

[0031] The relevant murine amino acids that can be used for comparison are shown in mVHEP and mVLEP in Figures 1a & 1b respectively, with the exception that, for the purposes of this discussion, the few italicised amino acids shown in mVHEP and mVLEP are considered to be non-murine. At these positions the residues considered to be murine are given in the table below, in the order in which the italicised residues appear in the Figures.

Position	Italicised residue shown in Figure	Corresponding murine residue
Heavy chain	M	V

(continued)

Position	Italicised residue shown in Figure	Corresponding murine residue
Heavy chain	Q	G
Light Chain	D	Q
Light Chain	S	T

[0032] Thus the percentage of humanisation of one or more framework regions may be reduced by amino acids substitutions that do not necessarily increase the percentage of murine residues present.

[0033] These may result from conservative non-murine amino acid substitutions and/or from non-conservative non-murine substitutions.

[0034] However conservative substitutions are most preferred.

[0035] Amino acids can be grouped as follows:

Group I (hydrophobic lateral chains): M, A, V, L, I;

Group II (neutral hydrophilic lateral chains): C, S, T, N, Q;

Group III (acid lateral chains): D, E;

Group IV (basic lateral chains): K, R;

Group V (residues that influence the orientation of the main chain): G, P; and

Group VI (aromatic lateral chains): F, Y, W.

[0036] Conservative amino acid substitutions entail substitutions between amino acid of the same group, whilst non conservative amino acid substitutions entail an exchange between members of different groups.

[0037] Whatever sequences are present in the different regions of the light and/or heavy chains, it is preferred that an antibody or derivative of the present invention has certain functional characteristics.

[0038] In addition to binding to TrkA, it is preferred that an antibody or derivative of the present invention is capable of blocking or reducing the binding of NGF to TrkA.

[0039] Preferably, it is capable of blocking or reducing one or more biological activities that would otherwise be induced by the binding of NGF to the TrkA receptor.

[0040] Thus it is preferred that it is an antagonist of one or more activities induced by NGF binding to TrkA (rather than an agonist). Thus the antibodies and derivatives thereof according to the invention suitably prevent the functional activation of TrkA. Inhibition of functional activation of TrkA by antibodies and derivatives thereof can lead to analgesia *in vivo*.

[0041] Various assay procedures can be used.

[0042] A standard assay is the classical PC12 *in vitro* assay in which PC12 cells are incubated with NGF and candidates are assessed to see if they are effective in reducing the extension of NGF-induced neuritic growth. This model was used in WO 00/73344, for example.

[0043] In another assay, preferred antibodies produce an OD450/630 nm value of greater than 0.1 in the TrkA-IgG binding assay illustrated by Figure 2. More preferably the OD450/630 nm value is greater than 0.2. Most preferably it is greater than 0.3.

[0044] In a further assay, preferred antibodies or derivatives thereof provide an increase in FACS staining of TF1 cells in the FACS based assay described in the Examples (see Table 2). This is preferably an increase of over 1.0 fold. More preferably it is an increase that is at least 1.5 fold, at least 2.0 fold or at least 2.5 fold. Most preferably it is at least 3.0 fold.

[0045] Additional assays include assays for pain reduction, as described later in connection with the medical uses of the present invention (It is particularly desirable for medical applications that the antibodies/derivatives thereof act as antagonists rather than agonists in respect of the pain response).

[0046] Desired antibodies/derivatives of the present invention are selective in that they bind with greater affinity to TrkA than to TrkB (Compare the black and white columns in Figure 2, for example).

[0047] For example they preferably have a binding affinity that is at least 2 times, at least 4 times, or at least 6 times as great for TrkA than for TrkB.

[0048] High binding affinities to TrkA relative to TrkB result in greater selectivity and a lower risk of undesired side effects.

[0049] Binding affinities can be readily assayed by comparative binding studies, such as those illustrated in Figure 2.

[0050] Turning now to highly preferred antibodies of the present invention, these comprise one of the following combinations of light and heavy chains: BXhVH3VL3, BXhVH5VL1 or BXhVH5VL3.

[0051] These gave the best results in the assay illustrated by Figure 3.

[0052] Preferred derivatives are derivatives of BXhVH3VL3, BXhVH5VL1 or BXhVH5VL3.

[0053] It will be appreciated from the foregoing discussion that a wide range of antibodies and derivatives thereof are within the scope of the present invention.

[0054] These have numerous applications, including those discussed below:

5 Medical applications

[0055] Antibodies or derivatives of the present invention can be used in medicine.

[0056] They can be used to treat various disorders/conditions, as set out in various categories below.

10 [0057] The invention thus provides a method of treatment of the below mentioned conditions which comprises administering to a subject, suitably a mammalian subject especially a human subject, in need thereof a therapeutically effective amount of an antibody or derivative as described herein such that the condition is thereby treated.

[0058] The invention also provides use of an antibody or derivative as described herein in the manufacture of a medicament for the treatment of the below mentioned conditions.

15 [0059] The invention also provides a kit of parts comprising an antibody or derivative as described herein together with instructions directing the use thereof by a subject for the treatment of the below mentioned conditions.

[0060] Here the term "treatment" includes therapeutic treatment of an existing disorder/condition. It also includes prophylactic treatment. It further includes the amelioration of one or more adverse symptoms, even if a patient is not cured of a given disorder/condition. For example, pain may be alleviated or reduced.

20 Pain

[0061] A preferred medical use is in the treatment of pain.

25 [0062] According to International Association for the Study of Pain ("IASP") pain is generally defined as "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage or both". The essential element in all forms of pain is the activation of specialized high-threshold receptors and nerve fibers to warn the organism of potential tissue damage. The involvement of inflammatory cells and processes is a common element in many pain states. The term "acute pain" means immediate, generally high threshold, pain brought about by injury such as a cut, crush, burn, or by chemical stimulation. The term "chronic pain," as used herein, means pain other than acute pain, both of inflammatory and neuropathic origin. It is understood that chronic pain often is of relatively long duration, for example, months or years and can be continuous or intermittent.

30 [0063] Antibodies of the present invention can be used to treat chronic pain or acute pain.

[0064] The treatment of chronic pain is preferred

[0065] The use of anti-TrkA antibodies in treating pain is discussed in WO 00/73344, in WO 05/061540 and in WO 06/131952 for example.

35 [0066] The pain may for example be associated with any of the following: pancreatitis, kidney stones, endometriosis, IBD, Crohn's disease, post surgical adhesions, gall bladder stones, headaches, dysmenorrhea, musculoskeletal pain, sprains, visceral pain, ovarian cysts, prostatitis, cystitis, interstitial cystitis, post-operative pain, migraine, trigeminal neuralgia, pain from burns and/or wounds, pain associated with trauma, neuropathic pain, pain associated with musculoskeletal diseases, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, periarticular pathologies, oncological pain, pain from bone metastases, HIV infection.

40 [0067] Various models are known for assessing pain and can be used in screening antibodies/derivatives thereof.

[0068] For example, the nociception hot plate test can be used, as disclosed in WO 00/73344, for example. The experiment can be carried out according to McMahon et al., Nature Medicine, 1, 774-780 (1995) using the antibody/derivative as immunoadhesin. The antibody/derivative is infused subcutaneously into hind paw of an adult rat for a period of three weeks or by an osmotic mini-pump. The nociception sensitivity is evaluated at intervals using a hot plate test (Eddy and Leimbach, J. Phar. Exp. Ther., 107, 385-393(1953)), which mimics hyperalgesia situations following inflammation or partial damage to the nerve. The nociceptive stimulus induces in such a case a response (paw licking and/or jumping) which presumes an integrated coordination higher than simple reflex. According to the test the animal is put in a pen having a plate heated to the desired temperature as base, usually 56°C. The latency of any of two responses (paw licking and jumping) is measured in control animals (treated with non relevant antibody) and in those treated with the anti-TrkA antibody/derivative.

50 [0069] As an alternative to the hot plate test, the nociceptive response to formalin can be assessed. This test is disclosed by Porro and Cavazzuti in Prog. Neurobiol., 41:565-607 (1993) and was used in WO 06/137106. It involves assessing the reduction in pain response by analyzing any subsequent reduction in paw licking when a given candidate is administered prior to testing. Saline is typically used as a negative control.

55 [0070] The Chronic Constriction Injury (CCI) model is also a well known animal model. It involves chronic constriction of the sciatic nerve and is used for assessment of chronic pain of a neuropathic nature. This model is described by Bennett and Xie in Pain, 33, 87-107 (1988). It was used in WO 06/131592, for example.

Cancer

[0071] The antibodies/derivatives can also be used in the treatment of cancer.

[0072] Various cancers express TrkA. The interaction of TrkA with NGF may be involved in tumour development (e.g. of prostate and pancreatic cancers). Indeed in certain forms of cancer, an excess of NGF can facilitate the growth and infiltration of nerve fibres. By blocking the action of NGF it is possible to significantly reduce the formation of neuromas.

[0073] Furthermore, as an alternative to simply providing a blocking effect, the antibodies/derivatives can be coupled to a cytotoxic agent and can be used to target cancer cells expressing TrkA, as discussed later in further detail.

[0074] It is not however necessary to couple the antibodies/derivatives to toxins. ADCC (antibody-dependent cell-mediated cytotoxicity) arises due to an immune response in which antibodies/derivatives, by coating target cells, can make them vulnerable to attack by the system (e.g. by T cells, by complement activation, etc.)

Neuronal disorders

[0075] The antibodies/derivatives can also be used in the treatment of various neuronal disorders.

[0076] As indicated above the antibodies/derivatives can be used to reduce the formation of neuromas.

[0077] They can also be used in the treatment of neurodegenerative disorders. As discussed earlier, NGF has potential use in the treatment of Alzheimer's disease, but has undesired agonist properties, including an increase in pain sensitivity. Antibodies/derivatives of the present invention may be useful in such treatments to reduce undesired agonist effects of NGF (see also the "Combination therapy" section below).

[0078] Furthermore, the antibodies/derivatives can be used to treat neuropathic pain, as discussed above. This may be associated with a lesion or a dysfunction of the nervous system.

Inflammatory Disorders

[0079] A still further application is in the treatment of inflammatory disorders.

NGF is released by mast cells, fibroblasts and other cell types in the peripheral sites where inflammatory processes occur. In particular, mast cells appear to play a fundamental role. They produce NGF and at the same time express functional TrkA receptors at their surface. The NGF/TrkA system appears to mediate mastocyte activation through an autocrine positive feedback mechanism which allows local amplification of the algogenic inflammatory signal. Examples of inflammatory disorders that may be treated include inflammatory forms of the urinary tract and of the pelvic region, osteoarthritis, rheumatoid arthritis, asthma.

Other disorders

[0080] As discussed earlier, NGF has potential use in the treatment of diabetes and leprosy, but has undesired agonist properties, including an increase in pain sensitivity. Antibodies/derivatives of the present invention may be useful in such treatments to reduce undesired agonist effects of NGF (see also the "Combination therapy" section below).

Combination therapy

[0081] Antibodies or derivatives thereof of the present invention may be used together with one or more other active agents in combination therapy. They may be used for simultaneous, sequential or concerted administration in medicine.

[0082] For example, the antibody or derivative may be combined with an analgesic opioid. WO 06/137106 explains that small amounts of molecules able to block TrkA biological activity can potentiate the analgesic effects of opioids.

[0083] Such opioids include one or more compounds selected from the following: morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nabulfina, propoxyphene, pentazocine, and their pharmaceutically acceptable derivatives thereof

(e.g. pharmaceutically acceptable salts thereof).

[0084] Alternatively, the antibody or derivative may be used in combination therapy with one or more non-opioid analgesic.

[0085] A further combination is that of the antibody or derivative with NGF. As discussed above, the use of NGF in the treatment of various disorders, including Alzheimer's disease, diabetes mellitus, leprosy, etc., had been proposed, but increases in pain sensitivity had been noted arising from agonist properties towards peripheral targets. Again, by using an antibody or derivative of the present invention, pain sensitivity can be reduced, thereby making NGF-based therapies more attractive.

[0086] A further combination is that of one or more antibodies or derivatives of the present invention together with one

or more other antibodies. A preferred combination is with one or more other anti-TrkA or anti-NGF antibodies. Such combinations may provide increased efficacy in treating one or more of the disorders discussed herein, relative to treatment with a single antibody. For example combinations of two or more antibodies found to be amongst the most effective in assay procedures used herein may be used.

Pharmaceutical compositions, vehicles and routes of administration

[0087] The antibodies/derivatives of the present invention can be administered by any appropriate route.

[0088] This includes (but is not limited to) intraperitoneal, intramuscular, intravenous, subcutaneous, intratracheal, oral, enteral, parenteral, intranasal or dermal administration.

[0089] Thus the invention provides a pharmaceutical composition comprising an antibody or derivative thereof together with a pharmaceutically acceptable carrier or excipient.

[0090] The antibodies/derivatives can typically be administered for local application by injection (intraperitoneal or intracranial-typically in a cerebral ventricle-or intrapericardiac or intrabursal) of liquid formulations or by ingestion of solid formulations (in the form of pills, tablets, capsules) or of liquid formulations (in the form of emulsions and solutions).

[0091] Compositions for parenteral administration commonly comprise a solution of immunoglobulin dissolved in a compatible, preferably aqueous solution. The concentration of the antibody/derivative in these formulations can vary from less than 0.005% to 15-20% w/v. It is selected mainly according to the volumes of the liquid, viscosity, etc, and according to the particular administration mode desired. Alternatively, the antibodies/derivatives can be prepared for administration in solid form. The antibodies can be combined with different inert or excipient substances, which can include ligands such as microcrystalline cellulose, gelatin or Arabic rubber; recipients such as lactose or starch; agents such as alginic acid, Primogel or corn starch; lubricants such as magnesium stearate, colloidal silicon dioxide; sweeteners such as saccharose or saccharin; or flavours, such as mint and methyl salicylate. Other pharmaceutical administration systems include hydrogel, hydroxymethylcellulose, liposomes, microcapsules, microemulsions, microspheres, etc.

[0092] Local injections directly at a site affected by a disorder /close thereto is a preferred mode of administration if a disorder is localised.

[0093] In contrast to anti-tumour based therapies, WO 06/131952 discusses the use of various anti-TrkA antibodies in the treatment of pain.

[0094] Here it is explained that anti-TrkA antibodies are suitably administered systemically. Systemic administration can be performed by injection, e.g. continuous intravenous infusion, bolus intravenous infusion, subcutaneous or intramuscular injection. Alternatively, other forms of administration (e.g. oral, mucosal, via inhalation, sublingually, etc.) may also be used.

[0095] If desired, however, delivery of the antibody/ derivative can be performed by local administration (e.g. intra-articular injection or subcutaneous, intramuscular injection) in the vicinity of affected tissues.

[0096] The anti-TrkA antibody/derivative will suitably be formulated in a pharmaceutical composition appropriate for the intended route of administration. Solutions for injection will suitably contain the antibody/derivative dissolved or dispersed in an aqueous medium (e.g. water for injection) as appropriate containing appropriate buffers and molarity modifiers (e.g. phosphate, salt and/or dextrose).

[0097] The treatment regime (i.e. dose, timing and repetition), can be represented by single or repeated administrations (e.g. injections) of the product by the chosen administration route.

[0098] The interval of dose administration can be subject to modifications depending on the extent and duration of the clinical response, as well as the particular individual and the individual clinical history.

[0099] Suitably the anti-TrkA antibody/derivative has a long duration of action. In particular the clinical effect of the antibody following administration may be as long as 21 days as determined from animal studies. Furthermore, anti-TrkA antibodies/derivatives may manifest clinical benefit for a longer period than that in which its presence can be detected in a relevant biological matrix such as serum or plasma following its administration.

[0100] In light of the intended long duration of action (i.e. an effect suitably lasting at least one week, or preferably at least two weeks e.g. at least three weeks or at least four weeks), suitably the antibody/derivative may be administered to subjects at a frequency of not more than once per week e.g. not more than once per two weeks or once per three weeks or once per four weeks.

[0101] A suitable daily dose of the anti-TrkA antibody/derivative will typically range from 0.1 mg/kg to 10 mg/kg body weight.

[0102] (Using humanised anti-TrkA antibodies and a CCI model it is reported in WO 06/131592 that significant analgesic properties were observed in experimental animals at a dosage of 2 mg/kg, although lower dosages may of course be preferred for humans.)

[0103] Turning now to administration in respect of tumours, administration may be through direct and localized injection into a tumour or a tissue near the tumour site. For systemic administration, doses vary from 0.05 mg/kg per day to 500 mg/kg per day, although dosages in the lower region of the range are preferred because they are easier to administer.

Dosages can be calibrated for example to guarantee a particular level in the plasma of the antibody/derivative (in the range of about 5-30 mg/ml, preferably between 10-15 mg/ml) and maintain this level for a given period of time until the clinical results are achieved.

[0104] Effective methods for measuring or assessing the stage of pancreatic or prostatic tumours are based on the measurement of the prostate specific antigen (PSA) in blood, on the measurement of the survival time for pancreas tumours, on the measurement of the slowing or inhibition of diffusion for metastases in the case of both tumour types.

[0105] For direct injection at the level of a tumour site, dosage depends on different factors including the type, stage and volume of the tumour, along with many other variables.

[0106] Depending on tumour volume, typical therapeutic doses may vary from 0.41 mg/ml to 10 mg/ml injections which can be administered with the necessary frequency.

[0107] Whatever the nature of the therapy, humanised antibodies/derivatives may be eliminated much more slowly and require lower dosages to maintain an effective level in the plasma than non-humanised antibodies. Moreover, with high affinity antibodies/derivatives, administration may be less frequent and less sizable than with antibodies having lower affinity.

[0108] The therapeutically effective dosage of each antibody/ derivative can be determined during the treatment by a skilled medical practitioner. If necessary, dosages can be reduced (e.g. to reduce side effects) or increased (to increase activity).

[0109] Prior to administration, preparations of antibodies/derivatives of the invention can be stored by being frozen or lyophilized. They may then be reconstituted immediately before use in a suitable buffer. Given that lyophilisation and reconstitution can result in a loss in activity, antibody administration levels can be calibrated to compensate for this fact. (For conventional immunoglobulins, IgM antibodies tend to have a greater loss of activity than IgG antibodies). A shelf life may also be assigned so that antibodies/derivatives are not used after a certain period of storage.

Diagnostic and prognostic applications

[0110] An antibody or derivative thereof of the present invention can be used in the diagnosis or prognosis of any of the diseases/ conditions discussed above in relation to medical uses.

[0111] For example it may be used to facilitate detection of TrkA positive tumour markers, as a precocious marker of the insurgence of Alzheimer's disease, etc.

[0112] It may also be used in the diagnosis of CIPA ("congenital insensitivity to pain with anhydrosis"). This is a hereditary, recessive, autosomal syndrome characterised by recurrent episodic fever, anhydrosis, the absence of reaction to nociceptive stimuli, mental retardation and a tendency to self-mutilation. It results from mutations in the TrkA gene. Indeed an antibody or derivative of the present invention may be used in the diagnosis or prognosis of a wide range of conditions involving aberrant expression of TrkA (compared to expression of TrkA in a healthy individual or a healthy tissue sample).

[0113] The present invention therefore includes within its scope a method comprising obtaining a biological sample obtained from a patient and contacting the sample with an antibody or derivative of the present invention.

[0114] If desired, the antibody/derivative may be immobilised. It may be provided in the form of a diagnostic kit.

[0115] The method may then include assaying the binding of the antibody / derivative to said sample in a quantitative or qualitative manner. If desired, this may be done with reference and/or to a positive control (indicating a healthy state) or a negative control (indicating the presence/likelihood of a disorder).

[0116] For diagnostic purposes, the antibodies/derivatives can be both marked with a detectable marker or can be unmarked. (The term "marker" is used herein to include labels or any other detectable moiety/moiety that can trigger a detectable change.)

[0117] Unmarked antibodies can be used in combination with other marked antibodies (secondary antibodies), which are reactive against humanised, or human antibodies (e. g. specific antibodies for the constant regions of human immunoglobulins).

[0118] Alternatively, antibodies can be marked directly. A wide variety of markers can be used, e. g. radionuclides, fluorophores, colourings, enzymes, enzymatic substrates, enzymatic factors, enzymatic inhibitors, ligands, etc.

[0119] In particular, for diagnostic or prognostic imaging applications, a detectable agent is conjugated to the antibody that is detectable or marked with a detectable radioisotope (e.g. a radioisotope such as of iodine, indium, technetium) or in paramagnetic manner (with paramagnetic atoms or ions, such as transition elements, actinides and rare earths, in particular, manganese II, copper II and cobalt II).

[0120] Imaging procedures may entail the intravenous, intraperitoneal or subcutaneous injection (in lymphatic drainage regions to identify lymph node metastases) and may use detectors of radionuclide emissions (such as scintillation β counters) in the case of immunoscintigraphy.

[0121] If a paramagnetic marking is used instead, an NMR spectrometer can be used.

Other applications

[0122] The antibodies/derivatives thereof may be used as starting points to develop further antibodies. Thus they may be used as design tools.

[0123] They may be screened by one or more binding/functional assays and may therefore be part of a drug development program.

[0124] They may be used for tissue typing, for forensic studies, etc.

They may be used as research tools

[0125] For example they may be used for further research into TrkA and/or into disorders in which TrkA binding to NGF (or other TrkA binding agents) may be implicated. They may be used to study binding and/or activation

[0126] All of the above applications of the antibodies/derivatives are within the scope of the present invention.

Nature of antibodies and antibody derivatives

[0127] It will be appreciated from the foregoing description that a wide range of antibodies and derivatives thereof can be used in the present invention.

[0128] For the avoidance of doubt the terms "antibodies" and "antibody derivatives" are discussed below in further detail.

Antibodies

[0129] Antibodies of the present invention can be in the form of any desired immunoglobulin structure.

[0130] IgG and IgM are however preferred, with IgG being the most preferred. Of the IgG isoforms, IgG1 is preferred, but other forms can be used including IgG4.

[0131] The antibodies are chimeric, i.e. they include one or more regions that are normally not associated with one another in nature. More specifically, one or more murine-derived CDR regions are present in the antibodies, but other regions (especially constant regions) are preferably human or humanised.

[0132] Humanised regions have more residues in common with a given human immunoglobulin region than with a corresponding mouse immunoglobulin region. Preferably, they have at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% identical with the human region at the amino acid sequence level. More preferably, there is 100% sequence identity over one or more non-CDR regions (e.g. constant regions).

[0133] In some cases, however it may be beneficial to introduce certain changes.

[0134] For example, it may be desirable to introduce changes that prevent/reduce one or more of the following:

- a) activation of the complement system
- b) complement mediated lysis
- c) activation of T cells
- d) binding to an Fc receptor.

[0135] Mutations indicated to allow one more of the above to be achieved are discussed in various patents. One or more of said mutations may therefore be included in antibodies/derivatives of the present invention

[0136] For example, US Patent No 6,194,551 proposes amino acid substitutions at amino acid positions 322, 329 and/or 331 (using the Kabat numbering system) of the constant heavy chain region of the IgG molecule and suggests that they can be used to prevent/reduce undesired activation of the complement system by abolishing Fc binding to C1q (see also Ward and Ghetie, *Therapeutic Immunology* 2: 77-94 (1995)). US Patent No 6,194,551 explains that proline is conserved at position 329 in human IgG's. This residue (which is glycosylated and may thereby be involved in activating the complement system) is preferably replaced with alanine. However, substitution with any other amino acid is contemplated, e.g., serine, threonine, asparagine, glycine or valine. US Patent No 6,194,551 explains that proline is also conserved at position 331 in human IgG1, IgG2 and IgG3, but not IgG4 (which has a serine residue at position 331). Residue 331 is preferably replaced by alanine or another amino acid, e.g. serine (for IgG regions other than IgG4), glycine or valine. A further possibility discussed is to introduce substitutions at position 322. Lysine 322 is conserved in human IgGs, and this residue is said to be preferably replaced by an alanine residue, although a substitution with any other amino acid residue is contemplated (e.g. serine, threonine, glycine or valine).

[0137] US Patent 6,491,916 discloses that mutations in the region spanning about position 230 to about position 240 of a humanised antibody can produce particular advantages. Here it is explained that comparisons of antibodies that bind to Fc to those that do not bind to Fc suggest that changes in this region result in anti-CD3 antibodies that do not activate T cells. For example, some of the preferred antibodies comprise a mutation at position 234, at position 235, or at both. Anti-CD3 antibodies comprising one, two, three, four, five, or more mutations at one or more of positions 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, or 240, are expected to have advantages. This patent also discloses that

an antibody having an IgG1 Fc region and mutated to have alanine at both positions 234 and 235 does not bind to the Clq component of complement and start the complement-mediated cascade. Further, it is explained that the mutation Lys 320 to Gln has an affinity for Clq only slightly weaker than the wild type but is non lytic.

[0138] US Patent 5,624,821 discloses that by changing any one of residues 318 (Glu), 320 (Lys) and 322 (Lys), to Ala, it is possible to abolish Clq binding. It points out that it is not necessary to replace the ionic residues only with Ala to abolish Clq binding, but that it will also be possible to use other alkyl-substituted non-ionic residues, such as Gly, Ile, Leu, or Val, or such aromatic non-polar residues as Phe, Tyr, Trp and Pro in place of any one of the three residues in order to abolish Clq binding. It will also be possible to use such polar non-ionic residues as Ser, Thr, Cys, and Met in place of residues 320 and 322, but not 318, in order to abolish Clq binding activity. US Patent 5,624,821 further discloses that replacing residue 297 (Asn) with Ala results in removal of lytic activity while only slightly reducing (about three fold weaker) affinity for Clq. It explains that it is thought this arises because the alteration destroys the glycosylation site and that the presence of carbohydrate is required for complement activation. It points out that any other substitution at this site will also destroy the glycosylation site. US Patent 5,624,821 also discloses that mutations on, adjacent or close sites in the hinge link region (e.g. replacing residues 234, 236 or 237 by Ala) indicate that alterations in residues 234, 235, 236 and 237 at least affect affinity for the Fc gamma R1 receptor.

[0139] Of course one or more amino acid changes (typically conservative amino acid changes) may be incorporated that do not substantially affect biological properties. Possible mutations are therefore not restricted to those discussed above.

Antibodies of whatever nature can be provided in monoclonal form (i.e. in combination with identical antibodies) or polyclonal form (i.e. in combination with different antibodies). Hybridomas capable of producing monoclonal antibodies of the present invention are also within the scope of the present invention.

Antibody derivatives

[0140] The term "antibody derivatives" is intended to allow for a wide range of structural changes that can be made relative to an antibody, provided that desired functional properties are retained.

[0141] Thus, for example, binding affinity to TrkA is desirably retained.

[0142] Preferably, the derivatives are also effective in one or more of the functional assays described herein.

[0143] For the avoidance of doubt it is noted that all of the following are considered to be derivatives of an antibody of the present invention:

- a) a fragment of said antibody
- b) a multimer comprising a plurality of fragments of said antibody (referred to herein as a "fragment multimer")
- c) a fusion product of said antibody, fragment or fragment multimer and another moiety
- d) a variant of said antibody, fragment, fragment multimer, or fusion product, having at least 75% sequence identity therewith.

[0144] Thus the term "derivative" is interpreted broadly.

[0145] Turning now to fragments of the present invention, these are preferably at least seven amino acids long (Thus they are at least as long as the shortest CDR region shown in Figures 1a & 1b for the heavy and light chains of the present invention). More preferably, they are at least ten, at least fifteen, or at least twenty amino acids long.

[0146] They can be produced, by means of proteolytic digestion starting from intact antibodies or by inserting stop codons in the desired positions in vectors bearing the coding DNA sequences for the variable regions of the heavy and light chain. This can be done after the CH₁ region to produce Fab fragments or after the hinge region to produce (Fab')₂ fragments.

[0147] Derivatives in the form of ScFv chains can be obtained by joining the variable regions of the heavy chain and of the light chain by means of a linker (Huston et al, PNAS, 85, 5879 (1988); Bird et al, Science, 242,423 (1988)). Fv or Fab fragments can be expressed in E. coli (Buchner and Rudolph, Bio/Technology, 9, 157 (1991); Skerra et al., Bio/Technology, 9, 273 (1991)) or also in eukaryotic cells, preferably mammal derived.

[0148] Indeed a very range of fragment forms is possible, including those discussed by Holliger & Hudson in Nature Biotechnology, Vol 23, No 9, 1126-1136 (2005).

[0149] These are all within the scope of the present invention. They can include fragments consisting of individual VH or VL chains (sometimes known as "domain antibodies" or "dAbs") or even fragments of said chains (e.g. individual CDR regions). Multimeric forms are also included, such as minibodies, bis(or higher)-ScFv, diabodies, triabodies, tetra-bodies, Fab multimers, etc. (referred to herein as "fragment multimers").

[0150] Furthermore, various other moieties can be covalently linked with antibodies/fragments of the present invention so as to provide beneficial properties. Such "fusion products" are within the scope of derivatives of the present invention. The moiety may for example be a diagnostic agent, a therapeutic agent, a marking agent, an agent that increases the

half life of the product, or an agent that reduces immunogenicity (preferably in a human host).

[0151] For example, fusion products in the form of PEGylated antibodies/fragments may be provided. PEG has been predominantly used to reduce the immunogenicity and increase the circulating half-lives of antibodies. It may also have a beneficial effect on the use of antibodies in certain clinical settings such as tumour targeting.

[0152] The parts of a fusion product can be linked together chemically. For example this may be done by cross-binding using heterobifunctional agents (e.g. SPDP, carbodiimide, glutaraldehyde, etc.).

[0153] In the case of fusion proteins, these are preferably made using genetic engineering techniques. Thus appropriate coding sequences based on the genetic code can be provided encoding the desired fusion protein and can then be cloned into a host cell using a suitable expression vector. Expression may be under the control of a constitutive or inducible promoter. The expressed fusion protein can be purified using standard techniques (e.g. by using immunofinity procedures). Cell-based or cell-free expression systems may be used.

[0154] Fusion proteins may for example comprise antibodies/fragments of the present invention fused to cytotoxins. Resultant fusion proteins may then be used to target cells that express TrkA receptors, e.g. TrkA expressing tumour cells.

[0155] The production of various cytotoxic immunotoxins is reported by Thorpe et al, Monoclonal Antibodies in Clinical Medicine, Academic Press, 168 (1982). Indeed a large number of cytotoxic agents are suitable for use in immunotoxins. Such agents include radionuclides such as iodine 131 or other isotopes of iodine, yttrium 90, rhenium 188 and bismuth 212 or other isotopes that emit alpha particles, a great number of chemotherapeutic drugs such as vindesine, methotrexate, adriamycin and cisplatin; cytotoxic proteins, such as proteins that inhibit ribosomes (e.g. pokeweed antiviral protein, Pseudomonas exotoxin A, diphtheria toxin, ricin A and clavin of vegetable origin), or agents active at the cell surface level (e.g. phospholipase enzymes such as Phospholipase C).

[0156] Sometimes the cytotoxic region of the immunotoxin can be immunogenic and consequently limit the clinical usefulness of the fusion protein in case of chronic or long term therapy.

[0157] An alternative to avoid the problem of the immunogenicity is to express in fusion with the binding domain of the antibody/derivative a protein able to interact with DNA and bind to this fusion protein the vector (e.g. plasmid) that contains the toxin expression cassette. The numerous positive charges of protamin, a human protein that binds DNA, can interact in stable fashion with the negative charges of the DNA, generating a fusion partner for the neutral charge antibody/derivative. This is much more stable and less immunogenic than the toxin itself. After internalization of the antibody-vector complex via receptor mediated endocytosis, the expression of the toxin causes the death of the cell.

[0158] Moreover, if desired, inducible or cell-specific promoters can be provided in the toxin expression cassette. This approach is aimed at maximizing the selective elimination of tumour cells while minimizing toxicity side effects (Chen et al, Gene Ther., 2, 116 (1995)).

[0159] Fusion proteins may also include fusions with other antibodies/derivatives. For example fusions of dAbs to specific antigens with other dAbs capable of binding long lasting serum proteins (e.g. serum albumin) have been used to increase serum half life.

[0160] Variable heavy and light chain sequences of the present invention may form part of multivalent antibodies having specificity for one or more antigens, one of which is TrkA, or one or more epitopes within TrkA.

[0161] Multivalent antibodies with specificity for one or more antigens, one of which is TrkA **Expression systems**

[0162] Many expression systems can be used to provide antibodies/derivatives of the present invention.

[0163] For example, prokaryotic systems can be used and are well characterized.

[0164] *E. coli* is one of the prokaryotic hosts that is particularly useful for cloning the DNA sequences of the present invention. Moreover, a great number of well characterized promoters is available, e. g. from the *lac* or *trp* operon or β -lactamase or λ phage. Typically, these promoters control expression and bear binding site for the ribosome, for the correct start and finish of transcription and translation. It is possible to increase the half-life of the humanised immunoglobulins of the invention produced in prokaryotic systems by conjugation with polyethylene glycol (PEG).

[0165] Other single-cell organisms, such as yeasts, can be used for expression. The host of choice is *Saccharomyces*, using suitable carriers provided with expression control, replication termination and origin sequences.

[0166] Phage-display libraries bearing sequences of the variable regions of immunoglobulins have been well reported and can be used in binding studies [Cesareni, FEBS Letts, 307, 66 (1992); Swimmer et al. PNAS, 89, 3756 (1992); Gram et al. PNAS, 89, 3576 (1992); Clackson et al. Nature, 352, 624 (1991); Scott & Smith, Science, 249, 386 (1990); Garrard et al. Bio/Techniques, 9,1373 (1991)].

[0167] Insect cell cultures can also be used, typically utilising cells of *S2 Drosophila* transfected in stable fashion or cells of *Spodoptera frugiperda* with the expression system based on the Baculovirus (Putlitz et al. Bio/Technology, 8, 651 (1990)).

[0168] Plants and cultures of vegetable cells can even be used (Larrick & Fry, Hum. Antibodies Hybridomas, 2, 172 (1991); Benvenuto et al. Plant Mol. Biol, 17 865 (1991); Durin et al. Plant Mol. Biol.; 15,281 (1990); Hiatt et al. Nature, 342,76 (1989))

[0169] It is also possible to use tissue cultures of mammal cells to express the polypeptides of the present invention. This can be advantageous in obtaining human glycosylation patterns. Different isotypes can be expressed. IgG1 has

proven to be the most effective isotype in the induction of the immune response (Winnacker, From Genes to Clones, VCH Publishers, NY, (1987)) whilst IgG4 is often used for diagnostic applications (Riechmann et al., Nature, 332,323 (1988)).

[0170] Mutated forms abolishing/reducing activation of complement may also be provided, as discussed earlier with reference to US Patent No 6,194,551., US Patent 5,624,821 and/or US Patent 6,491,916.

[0171] In particular, mammalian cells are preferred. A great number of host cell lines have been developed for the secretion of intact immunoglobulins, among them are CHO cell lines, several COS cell lines, the HeLa cells, myeloma cell lines (NSO, SP/2, YB/0 e P3X63.Ag8.653), transformed B cells or hybridomas. Expression vectors for these cells can include expression control sequences, such as a replication origin, a promoter, an enhancer (Queen et al, PNAS, 86:10029 (1989)), and the sequences required for ribosome binding, RNA splicing and polyadenylation, and sequences for transcription termination. The expression control sequences of choice are promoters derived from immunoglobulin genes and from viruses, such as SV40, Adenovirus, Bovine Papilloma Virus, Cytomegalovirus and the like. Generally, the expression vector includes a selectable marker, such as the resistance to neomycin.

[0172] For the expression of humanised antibodies, it is preferable to cultivate the mammal cell lines with a serum-free medium. For example, the HUDREG-55 cell line can easily be grown in Serum-Free and Protein-Free Hybridoma Medium Cat. No. S-2897 from Sigma (St. Louis, Mo.).

Nucleic Acids, Vectors, Transgenic animals

[0173] Nucleic acid sequences encoding the antibodies/derivatives/antibody chains of the present invention can be produced by standard techniques, given that the amino acid sequences for the key variable regions are provided herein and that corresponding coding sequences can be provided using the genetic code. These sequences can be incorporated into expression vectors and/or cloned into cells.

[0174] Indeed techniques for producing and cloning "reshaped antibodies" with rodent CDR regions and humanised framework regions are now well known. They are discussed for example in Jones, Dear, Foote, Neuberger and Winter, Nature, 321, 522-4 (1986); in Riechmann, Clark, Waldman and Winter, Nature, 332, 323-327 (1988) and in Verhoeven, Milstein and Winter, Science, 239, 1534-1536 (1988).

[0175] Such nucleic acids can be incorporated into expression vectors, including plasmids, phage, etc., as is well known in the art and is discussed above.

[0176] Nucleic acids of the present invention can also be used to design probes or primers. These can be used for example to isolate or amplify nucleic acids of the present invention.

[0177] Probes or primers are therefore within the scope of the present invention. Typically they are at least 10, at least 15 or at least 20 bases long. Preferably they hybridise under stringent conditions to nucleic acid strands that encode antibodies/derivatives of the present invention or to complementary strands thereof. One example of stringent hybridisation conditions involves using a pre-washing solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0) and attempting hybridisation overnight at 55°C using 5 X SSC. However, there are many other possibilities. Some of these are listed in Table 1 of WO98/45435, for example. (See especially the conditions set out under A-F of that table and, less preferably, those listed under G to L or M to R).

[0178] In a further aspect of the present invention, the nucleic acids can advantageously be used to provide transgenes for use in producing non-human transgenic animals, preferably mice. Here the antibody/derivative may be expressed in an inducible way, or under the control of constitutive promoters.

[0179] Such animals can be advantageously used to study and test drugs for human pathologies wherein the NGF/TrkA interaction is inhibited and, particularly, neurodegenerative pathologies.

The antibody/derivative can be advantageously expressed in a retrievable body fluid such as milk or serum, from which it can be retrieved and purified using standard techniques.

[0180] Transgenes used to produce the transgenic animals may comprise the relevant coding sequence(s) operatively bound to a promoter, usually in combination with an enhancer sequence, such as that of the rodent immunoglobulin or the promoter/enhancer of the casein gene (Buhler et al., Bio/Technology; 8,140 (1990); Meade et al., Bio/Technology, 8, 443 (1990)).

[0181] The transgenes can be transferred into the cells or embryos by means of homologous recombination. A wide range of non-human transgenic animals can be produced, including mice, rats, sheep, cows, goats, etc. (see WO 91/08216).

[0182] It will be appreciated from the foregoing description that the present invention provides a range of new antibodies, derivatives, nucleic acids, etc.

[0183] If desired, these can be provided in substantially purified form. For the purposes of the present invention this means that they are the majority of the dry weight of a particular composition. For example they may represent at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of said dry weight.

[0184] They may be provided in isolated form. This means that they are removed from one or more other components

with which they may be normally associated in nature (for example a nucleic acid may be provided in a form that is isolated from a cell).

[0185] They may be provided in a variety of other forms. For example they may be fused to heterologous moieties and/or they may be immobilised.

[0186] All of the above forms are within the scope of the present invention.

[0187] The present invention will now be described by way of example only, with reference to the accompanying drawings, wherein:

Figures 1a & 1b show amino acid sequence alignments for various heavy and light chains.

Figure 2 shows the results for antigen binding specificity towards TrkA-IgG in respect of supernatants from various clones resulting from an experiment involving transient expression of the humanised MNAC13 variants in COS-7 cells.

Figure 3 the results of an experiment in which cellular binding of the antibodies to TrkA expressed on TF-1 cells was analysed by cytofluorimetric analysis.

Figure 4 shows the results of a further analysis in which the best binders identified from

Figure 3 (BXhVH3VL3, BXhVH5VL1, BXhVH5VL3, and HuMNACWOv) were compared to HuMNACWO.

Figure 5 shows the results of an assay in which different humanised candidates were assayed in parallel with murine MNAC13 antibody (muMNACEP), chimMNAC 13, HuMNACWO, and Human IgG1 as standard control.

Figure 6 shows the heavy and light chains for BXhVH5VL1, including the constant regions (the first amino acid of the constant region is underlined.)

Figure 7 shows the heavy chain for BXhVH5VL1 N297A, including the constant region (the first amino acid of the constant region is underlined and the 297A position is bold and underlined).

Figure 8 shows BXhVH5VL1 and BXhVH5VL1 N297A binding to cell lines expressing huTrkA.

Figure 9 shows the effect of various antibodies on NGF-induced MIP-1 β production in human mast cell line HMC-1.

Figure 10 shows binding of BXhVH5VL1 to cell bound Fc receptors on THP1 cell line compared to BXhVH5VL1 N297A.

Figure 11 shows an experiment demonstrating the analgesic effect of local intradermic injection of BXhVH5VL1 N297A or control hIgG when co-injected with rhNGF

Figure 12 shows an experiment demonstrating the analgesic effect of local intradermic injection of muMNACEP or control mIgG when co-injected with rhNGF

Figure 13 shows an experiment demonstrating the analgesic effect of systemic administration of BXhVH5VL1 N297A when compared to control hIgG in an animal model of NGF-induced pain.

Figure 14 shows an experiment demonstrating the analgesic effect of systemic administration of muMNACEP when compared to control hIgG in an animal model of NGF-induced pain.

Examples

[0188] Before discussing the examples in detail, some of the nomenclature used therein is set out below:

muMNACEP

[0189] This term is used to indicate the murine antibody MNAC13, as disclosed in EP1181318 The heavy chain variable region of this antibody is referred to herein as mVHEP (SEQ ID NO. 15). The light chain variable region is referred to herein as mVLEP (SEQ ID NO. 16).

HuMNACWO

[0190] This term is used to indicate the humanised antibody MNAC13 disclosed in WO 05/061540

[0191] The heavy chain variable region of this antibody is referred to herein as HuVHWO (SEQ ID NO. 17). The light chain variable region is referred to herein as HuVLWO (SEQ ID NO. 18)

HuMNACWOv

[0192] This terms is used to indicate a variant of the antibody disclosed in HuMNACWO (see above) in which the heavy chain CDR3 region has been replaced with a CDR3 region corresponding to that present in muMNACEP. The variant is novel and is within the scope of the present invention.

[0193] The heavy chain variable region of this antibody is referred to herein as HuVHWOv(SEQ ID NO. 6). The light chain variable region can be referred to herein as HuVLWOv. However, in order to avoid duplication, it is not shown in

Figure 1b, because it is the same as HuVLWO (SEQ ID NO. 18).

ChimMNAC13

[0194] This corresponds to muMNACEP, but has human constant regions instead of mouse constant regions. The heavy chain variable region of this antibody is referred to herein as mVHEP (SEQ ID NO. 15). The light chain is referred to herein as mVLEP (SEQ ID NO. 16). 3-23*01 (SEQ ID NO. 19), JH4 (SEQ ID NO. 20), L6*01 (SEQ ID NO. 21) and JK1 (SEQ ID NO. 22)

[0195] These are coding sequences derived from human germline genes.

[0196] They are used for assessing degrees of humanisation in Table 1. Thus if there are no changes relative to a human germline sequence it is considered that there is 100% humanisation.

$$\left[\frac{\text{The percentage humanisation} = \frac{\text{number of changes}}{\text{total number of residues compared}} \times 100 \right]$$

[0197] The table below shows the percentage humanisation for the different variants:

Table 1

Sequence variant	Number of murine AA in the FW/number of total AA in the FW	% Humanisation (related to FW sequence)	Number of murine AA including CDR AA/number of total AA in the variable region	% humanisation (related to complete variable sequence)
BXhVH1	0/87	100	36/123	70.7
BXhVH2	3/87	96.6	39/123	68.3
BXhVH3	3/87	96.6	39/123	68.3
BXhVH4	3/87	96.6	39/123	68.3
BXhVH5	5/87	94.2	41/123	66.7
BXhVHWO	12/87	86.2	48/123	61.0
BXhVL1	0/80	100	26/106	75.5
BXhVL2	4/80	95	30/106	71.7
BXhVL3	6/80	92.5	32/106	69.8
BXhVL4	6/80	92.5	32/106	69.8
BXhVL5	6/80	92.5	32/106	69.8
BXhVL6	8/80	90	34/106	67.9
BXhVL7	8/80	90	34/106	67.9
BXhVL8	11/80	86.2	37/106	65.1
BXhVLWO	9/80	88.8	35/106	67

[0198] It can be seen that all of the variant variable chains have a degree of humanisation over the framework regions of over 85%.

"BX" sequences

[0199] The sequences labelled with a code beginning with "BX" are novel sequences of the present invention. The letters following "BX" are either VH or VL to indicate a heavy or light variable chain respectively. The sequences are then simply numbered consecutively in the order in which they are shown in Figures 1a & 1b for a given chain.

[0200] There are five heavy chain sequences. Thus they are numbered:

BXhVH1 (SEQ ID NO. 1)
 BXhVH2 (SEQ ID NO. 2)
 BXhVH3 (SEQ ID NO. 3)
 BXhVH4 (SEQ ID NO. 4)

BXhVH5 (SEQ ID NO. 5)

[0201] There are eight light chain sequences. Thus they are numbered:

5 BXhVL1 (SEQ ID NO. 7)
 BXhVL2 (SEQ ID NO. 8)
 BXhVL3 (SEQ ID NO. 9)
 BXhVL4 (SEQ ID NO. 10)
 BXhVL5 (SEQ ID NO. 11)
 10 BXhVL6 (SEQ ID NO. 12)
 BXhVL7 (SEQ ID NO. 13)
 BXhVL8 (SEQ ID NO. 14)

[0202] The chains can be combined in antibodies or derivatives thereof.

15 [0203] The forty possible combinations have all been produced and are:

20 BXhVH1VL1, BXhVH1VL2, BXhVH1VL3, BXhVH1VL4, BXhVH1VL5, BXhVH1VL6, BXhVH1VL7, BXhVH1VL8,
 BXhVH2VL1, BXhVH2VL2, BXhVH2VL3, BXhVH2VL4, BXhVH2VL5, BXhVH2VL6, BXhVH2VL7, BXhVH2VL8,
 BXhVH3VL1, BXhVH3VL2, BXhVH3VL3, BXhVH3VL4, BXhVH3VL5, BXhVH3VL6, BXhVH3VL7, BXhVH3VL8,
 20 BXhVH4VL1, BXhVH4VL2, BXhVH4VL3, BXhVH4VL4, BXhVH4VL5, BXhVH4VL6, BXhVH4VL7, BXhVH4VL8,
 BXhVH5VL1, BXhVH5VL2, BXhVH5VL3, BXhVH5VL4, BXhVH5VL5, BXhVH5VL6, BXhVH5VL7, BXhVH5VL8.

"N297A"

25 [0204] The designation "N297A" after the name of an antibody indicated that position 297 of the heavy chain constant region is mutated from N to A.

The sequence of BXhVH5VL1 N297A is provided as SEQ ID No. 23.

Expression vectors

30 [0205] The appropriate coding sequences were fused to a sequence coding for a secretory signal 5' and a splice donor sequence 3' to the cDNA for cloning into an antibody expression system.
 The DNA fragments were cloned into IgG1 expression vectors.
 These expression vectors were based on genomic sequences encoding the human constant domains and cloning
 35 cassettes for the insertion of the selected cDNA fragments of the hVH and hVL sequences.

Transient expression of the humanised MNAC13 variants in COS-7 cells and determination of antibody titers

40 [0206] Each combination of Heavy and Light chain was transiently transfected in COS-7 cells and antibody titer was determined.

[0207] The expression vectors coding for the light chain and for the heavy chain were transiently cotransfected into COS-7 cells by lipofection using Lipofectamin according to the manufacturer's instructions (Invitrogen, Germany) in a 24-well format.

45 After transfection the medium was replaced by DMEM containing 10%FCS and 2% L-glutamine and the supernatants of the COS-7 cells were collected 4 days after transfection.

[0208] The antibody titer of the humanised antibodies secreted into the supernatants of transfected COS-7 cells was analyzed by a sandwich ELISA.

50 [0209] Briefly, a mouse anti-human kappa chain recognizing antibody (BD) was immobilized on a 96 well plate, blocked and incubated with diluted supernatant of transfected COS-7 cells. The presence of antibodies was detected by a POD conjugated rabbit anti-human IgG (H+L) antibody (Dianova, Germany). A chimeric control antibody was used as a standard in concentrations from 1 to 10 ng/ml. The determined antibody concentrations were further adjusted by an internal standard sample having a standardized antibody concentration.

Example 1

Comparison of humanised antibody binding towards TrkA-IgG in ELISA

[0210] Based on the determined antibody concentration, supernatants of all samples were adjusted to the same

antibody concentration.

[0211] The binding activities of all humanised antibody variants were analyzed by a TrkA-IgG antigen ELISA. They were compared to the binding activities of the ChimMNAC13 and HuMNACWOv.

[0212] Antibodies and antigens were thawed, aliquoted and stored at - 20°C. Aliquots of the antibodies in use were stored at 4 °C for a maximum of two weeks.

[0213] Antigen ELISA was performed as follows: Maxisorb plates (Nunc, Germany) were coated with 0.125, 0.25, 0.5, and 1 µg/ml TrkA-IgG. To check the specificity of antibody-antigen binding TrkB-IgG (1µg/ml) as a negative control was used.

[0214] Transiently expressed antibody variants were used at 1, 10, and 100 ng/ml.

[0215] Detailed procedure as follows:

Coating

[0216] Plates: Nunc MaxiSorp 96well

100µl/well of TrkA-IgG at 2 µg/ml in Carbonate Buffer 0.1M pH 9.6 (TrkB-IgG used as negative control)

Seal plate and incubate overnight at +4°C

Wash 3 times with 200 µl of wash buffer

Blocking

[0217] Block plates by adding 200µl of SuperBlock Blocking Buffer in PBS. (Pierce Prod # 37515) to each well.

Immediately empty the plate by inversion.

Repeat two additional times.

Incubate at 37°C for 2 hours.

Primary Antibody

[0218] Discard supernatant and add 100µl of purified mAb appropriately diluted in TEST Buffer (standard curve range: 50-5000 pg/ml)

Seal plate and incubate at 37°C for 2 hours.

(In order to increase sensitivity incubate overnight at +4°C)

Wash 4 times with wash buffer

Secondary Antibody

[0219] Add 100µl of HRP-conjugated Goat anti mouse IgG (Pierce cat. 31430) diluted 1:10000 in TEST Buffer

Incubate at 37°C for 1 hour.

Wash 4 times with wash buffer.

Development

[0220] Add 100µl of Substrate solution to each well. Incubate at room temperature.

Stop the reaction with 100µl of H₂SO₄ 2M.

Determine the optical density of each well using a microtiter reader at 450 nm.

Results

[0221] The results for supernatants from the various clones evaluated for antigen binding specificity by using the ELISA assay are shown in Figure 2.

[0222] Briefly, the specific antigen TrkA-IgG (black bars) and the negative control TRKB-IgG (white bars) were coated at 1 µg/ml concentration on different 96-well plates.

[0223] Antibodies supernatants were quantified, appropriately diluted, and tested at 5 ng/ml concentration. After washing, binding was detected with the appropriated HRP-labeled secondary antibody, revealed by a chromogenic reaction and quantified by OD450/630 nm measure.

[0224] The majority of the humanised antibodies show a comparable selective affinity for high density TrkA antigen.

[0225] In addition, their binding specificity is not significantly different from parental murine anti-human TrkA antibody and its chimeric isoform, indicating that antigen selectivity has been fully preserved along the humanisation procedure.

Example 2**Cellular binding assay of new candidates by cytofluorimetric analysis of TrkA surface expression on TF-1 cells***Procedure*

[0226] Harvest cells from culture, preparing a single cell suspension.

(In order to obtain maximum antigen expression split cells 1:3 the day before).

Distribute $0.3-0.4 \times 10^6$ cells/sample and wash 1X with cold FACS buffer (PBS pH 7.4 + 0.1% NaN₃ + 0.1% BSA).

Centrifuge at 350 x g for 5 min.

Discard supernatant and Keep tubes on ice.

Fc Receptors Blocking

[0227] Add 50 µl/sample of Human IgG [300 µg/ml] in FACS buffer and mix by gently vortexing.

Incubate at 4°C for 15 min.

Primary Antibody

[0228] Add 100 µl/sample of Primary Antibody muMNAC13 [4 µg/ml] in FACS buffer and mix by gently vortexing.

As negative control use purified mouse IgG1 isotype control at the same concentration. Incubate at 4°C for 30 min.

Wash 2X with 1ml of FACS buffer, spin 5 min at 350 x g, and discard the supernatant.

Secondary Antibody

[0229] Add 100 µl/sample of Donkey anti Mouse IgG (H+L) R-Phycoerythrin conjugated

Jackson ImmunoResearch cat.# 715-116-151 in FACS buffer and mix by gently vortexing.

Incubate at 4°C for 30 min.

Wash 2X with 1ml of FACS buffer, spin 5 min at 350 x g, and discard the supernatant. Re-suspend in 0.5 ml of FACS Buffer.

Acquire sample data on flow cytometer.

Results

[0230] TF-1 cells were stained with supernatants from all the clones as well as HuMNACWO and HuMNACWOv antibodies as controls (4 µg/ml) for 30 minutes at 4°C.

[0231] Staining was revealed by an appropriate PE-labeled secondary antibody and quantified by cytofluorimetric analysis to evaluate the fluorescence intensity of the binding.

[0232] The results are shown in Figure 3, which is based upon the table below.

Table 2

N°.	Variants	Geo Mean Fluorescence				Fold Increase		
		Mean	±	S.D.		Mean	±	S.D.
1	mVHEP/mVLEP	11.0	±	2.2		3.2	±	0.7
2	hVHWOv/hVLWO	8.9	±	1.9		2.6	±	0.6
3	hVH1/hVL1	5.7	±	0.4		1.7	±	0.1
4	hVH1/hVL2	4.6	±	0.4		1.3	±	0.1
5	hVH1/hVL3	6.1	±	0.6		1.8	±	0.2
6	hVH1/hVL4	5.1	±	0.5		1.5	±	0.2
7	hVH1/hVL5	4.5	±	0.3		1.3	±	0.1
8	hVH1/hVL6	4.9	±	0.4		1.4	±	0.1
9	hVH1/hVL7	5.1	±	0.4		1.5	±	0.1
10	hVH1/hVL8	5.2	±	0.1		1.5	±	0.0

EP 2 252 633 B9

(continued)

N°.	Variants	Geo Mean Fluorescence				Fold Increase		
		Mean	±	S.D.		Mean	±	S.D.
11	hVH2/hVL1	9.2	±	1.3		2.6	±	0.4
12	hVH2/hVL2	6.4	±	0.7		1.8	±	0.2
13	hVH2/hVL3	10.8	±	1.3		3.1	±	0.4
14	hVH2/hVL4	6.1	±	0.3		1.8	±	0.1
15	hVH2/hVL5	6.4	±	0.2		1.8	±	0.1
16	hVH2/hVL6	6.4	±	0.7		1.8	±	0.2
17	hVH2/hVL7	6.5	±	0.8		1.9	±	0.3
18	hVH2/hVL8	6.5	±	1.0		1.9	±	0.3
19	hVH3/hVL1	8.6	±	1.5		2.5	±	0.5
20	hVH3/hVL2	7.1	±	2.1		2.0	±	0.6
21	hVH3/hVL3	12.6	±	0.6		3.6	±	0.2
22	hVH3/hVL4	7.1	±	0.1		2.0	±	0.0
23	hVH3/hVL5	6.9	±	0.5		2.0	±	0.2
24	hVH3/hVL6	6.4	±	0.5		1.8	±	0.2
25	hVH3/hVL7	7.1	±	1.0		2.0	±	0.3
26	hVH3/hVL8	6.5	±	1.2		1.9	±	0.3
27	hVH4/hVL1	10.4	±	2.4		3.0	±	0.7
28	hVH4/hVL2	8.3	±	2.5		2.4	±	0.7
29	hVH4/hVL3	10.9	±	3.0		3.1	±	0.9
30	hVH4/hVL4	8.0	±	2.2		2.3	±	0.6
31	hVH4/hVL5	8.6	±	1.7		2.5	±	0.5
32	hVH4/hVL6	8.0	±	1.4		2.3	±	0.4
33	hVH4/hVL7	8.7	±	2.5		2.5	±	0.7
34	hVH4/hVL8	8.3	±	1.9		2.4	±	0.6
35	hVH5/hVL1	11.3	±	2.7		3.2	±	0.8
36	hVH5/hVL2	8.6	±	2.3		2.5	±	0.7
37	hVH5/hVL3	13.7	±	2.1		3.9	±	0.6
38	hVH5/hVL4	9.1	±	2.2		2.6	±	0.7
39	hVH5/hVL5	8.3	±	2.0		2.4	±	0.6
40	hVH5/hVL6	9.1	±	1.5		2.6	±	0.5
41	hVH5/hVL7	8.6	±	2.0		2.5	±	0.6
42	hVH5/hVL8	8.3	±	1.6		2.4	±	0.5
43	hulG	3.5	±	0.0		1.0	±	0.0

[0233] The results showed that all the clones tested as well as HuMNACWOv positively detected the membrane-associated TrkA receptors on TF1 cells though to a different extent. HuMNACWO is not able to stain TF1cells, which have a low density of surface TrkA receptors.

[0234] To further confirm, out of 40 clones tested, the best binders were selected to be further analyzed.

[0235] As evaluated in two separate experiments (Figure 4) BXhVH3VL3, BXhVH5VL1, BXhVH5VL3, and HuMNAC-

WOv were compared with HuMNACWO.

The selected leads were confirmed good binders and slightly better performers when compared to HuMNACWOv.

[0236] The humanized antibody isoforms BXhVH5VL1 N297A and BXhVH5VL1 together with the reference antibodies muMNACEP and HuMNACWO were also assayed for binding capability on TF-1, HMC-1 and PC12-hTrkA cell lines which express different levels of surface receptor hTrkA.

[0237] As shown in Figure 8, BXhVH5VL1 N297A and BXhVH5VL1 antibodies comparably bind all the tested cell lines, independently of the receptor density on the cellular surface. Both antibodies appear to bind more efficiently when compared to the parental muMNACEP. HuMNACWO only binds high surface receptor density cell line PC12-hTrkA.

Example 3

Comparison of humanised antibody biological activity in vitro with a proliferation assay on TF1 cells

[0238] To measure the ability of anti-human TrkA monoclonal antibodies to block cell surface TrkA- β -NGF mediated biological activity, a cell proliferation assay using a factor-dependent human erythroleukemic cell line, TF-1 (Kitamura, T. et al., 1989, J. Cell Physiol. 140:323-334) was used.

[0239] TF-1 cells were incubated with various concentrations of the antibodies for 0.5 hour at 37° C in a 96 flat well culture plate.

[0240] Following this pre-incubation period, recombinant human β -NGF (rec-hu- β -NGF, R&D Systems) was added to the cell-antibody mixture.

[0241] The assay mixture in a total volume of 200 μ L, containing antibody at different concentrations indicated, human β -NGF at 5.0 ng/mL and TF-1 cells at 5 x 10³ cells/well, was incubated at 37°C for 5 days in a humidified CO₂ incubator.

[0242] After that period the plates were centrifuged and after removal of the supernatant frozen at - 80°C in order to lyse the cells.

[0243] CyQUANT Cell Proliferation Assay Kit (Molecular Probes) was used for measuring cell proliferation according to the manufacturer's instructions.

[0244] This experiment was performed twice.

Results

[0245] Different humanised candidates were assayed in parallel with murine MNAC13 antibody (muMNACEP), chimMNAC13, HuMNACWO and Human IgG1 as standard control (Figure 5).

[0246] The IC₅₀ were calculated for each curve and the results are given in the table overleaf.

[0247] It was found that antibody BXhVH5VL1 was the best performer among the candidates.

[0248] The heavy and light chains for this antibody are therefore shown in Figure 6.

[0249] The average IC₅₀ for murine MNAC13 over a series of experiments was 0.54 \pm 0.47 μ g/ml.

Table 3

Proliferation assay on TF1 cells IC ₅₀ (μ g/ml)		
	<u>Mean</u>	<u>SD</u>
muMNACEP	0.54	0.47
	<u>EXP-1</u>	<u>EXP-2</u>
ChimMNAC13	0.06	0.58
BXhVH5VL1	0.17	1.84
BXhVH3VL3	0.41	2.38
BXhVH5VL3	1.40	1.21
HuMNACWO	-	-
HuIgGstd	-	-

Example 4**Surface plasmon resonance analysis**

[0250] Surface plasmon resonance analysis was used to measure the association and dissociation rate constants for binding kinetics of the different antibodies (murine, chimeric, 5 humanised variants) towards TrkA-IgG using BIACORE 2000 (Biacore AB, Uppsala, Sweden). TrkA-IgG was immobilised on a CM-5 sensor chip according to manufacturer's conditions, in a way to achieve an immobilization density of 1100 RU. Each antibody sample was analyzed in antibody concentration ranges of 20-0.63 $\mu\text{g/ml}$. Calculations from the sensograms were performed by using the BIA evaluation version 3 (1999) software.

[0251] Analysis of the individual sets of sensograms was performed with the BIA evaluation version 3 (1999) software. Among the different models tested to fit the kinetics data, the best fitting was obtained with the "separated 1:1" algorithm. In this model, only a defined range of the early association and dissociation curves was used for the calculation. It is assumed that during these early phases of the curve, the overlay effects like mass transfer, rebinding or others do not affect the calculations.

Results

[0252] The dissociation constant (K_D) was determined for various antibodies and is set out in the table overleaf in the order in order of increasing value.

[0253] The K_D value has molar units (M), which correspond to the concentration of ligand at which a binding site on a particular protein is half occupied. The smaller the value, the more tightly bound the ligand, or the higher the affinity between ligand and protein (here between antigen and antibody).

Table 4

Antibody	K_{on} (1/Ms)	K_{off} (1/s)	K_D [M]
ChimMNAC13	2.68×10^5	3.53×10^{-4}	1.51×10^{-10}
MNAC13	8.50×10^5	1.67×10^{-4}	2.50×10^{-10}
BXhVH5VL1	7.68×10^5	4.70×10^{-4}	6.15×10^{-10}
BXhVH5VL3	1.00×10^6	6.38×10^{-4}	6.62×10^{-10}
BXhVH3VL3	3.25×10^5	4.42×10^{-4}	1.45×10^{-9}
HuMNACWOv	1.62×10^6	3.86×10^{-3}	2.48×10^{-9}
HuMNACWO (separate experiment)	7.39×10^5	3.09×10^{-2}	4.18×10^{-8}

[0254] It can be seen from the above table the calculated K_D for the murine and the chimeric isoforms are very comparable with one another.

[0255] They are slightly lower but of the same order of magnitude as the humanised variants BXhVH5VL1 and BXhVH5VL3.

[0256] On the contrary, the humanised variants HuMNACWOv and BXhVH3VL3 display a one order of magnitude higher K_D than that observed for the murine and the chimeric variants.

[0257] However, the K_D values here are still lower than for the prior art humanised antibody HuMNACWO.

[0258] Indeed, preferred K_D values for antibodies/variants of the present invention using this model are below 4.18×10^{-8} (thus they are lower than for the value for the humanised prior art antibody HuMNACWO).

[0259] More preferably they are below 2.48×10^{-9} (thus they are lower than the HuMNACWOv, which is a variant of HuMNACWO with the same framework regions, but with changes in the third CDR of the heavy chain).

[0260] Most preferably the K_D values are below 1×10^{-9} (thus they are of the same general order of magnitude as for the murine and the chimeric isoforms).

Consistently, the ranking given in the above table, which is based on the calculated data using the "separated" algorithm, reflected very well the ranking obtained by visual inspections of the sensograms of all investigated variants in overlay plots.

Example 5**Comparison of humanised antibody biological activity in vitro with a chemokine secretion assay on HMC-1 mast cell line**

[0261] NGF acts as an important intermediate in inflammatory pain, contributing to both peripheral and central sensitization. The sensitization of peripheral nociceptors can be very rapid and can involve non-neural cells such as mast cells.

[0262] To measure the ability of anti-human TrkA monoclonal antibodies to inhibit β -NGF-induced MIP1 α secretion, a biological assay using the mast cell line, HMC-1 (Ahamed, J. et al., J Immunol. 2004 Jun 1;172(11):6961-8.) was used.

[0263] HMC-1 cells (0.1×10^6 /well) were plated in triplicate in complete growth medium in a 96 flat well culture plate and incubated with various concentrations of monoclonal antibody for 0.5 hour at 37° C.

[0264] Following this pre-incubation period, recombinant human β -NGF (rec-hu- β -NGF, R&D Systems) was added to the cell-antibody mixture to a final concentration of 50 ng/ml and incubation at 37° C was extended for 6 hours in a humidified CO2 incubator.

[0265] Supernatants were then harvested and levels of MIP-1 β were quantified by sandwich ELISA using a DuoSet® Elisa Kit for Human CCL4/MIP1- β from R&D System (Cat. Nr.DY271).

[0266] Data obtained were expressed as % of response and analyzed with GraphPad Prism 5 software using a nonlinear regression analysis, log(inhibitor) vs. normalized response-variable slope equation.

Results

[0267] BXhVH5VL1 N297A antibody was assayed in parallel with murine muMNACEP, HuMNACWO, and Human IgG1 as standard control. The IC50 values were calculated for each curve and the results are shown in Figure 9. The inhibitory activity of BXhVH5VL1 N297A was significantly higher than that of the humanised antibody HuMNACWO.

Example 6**BXhVH5VL1 N297A and BXhVH5VL1 in vitro characterization. Evaluation of binding to cellular FcRs on THP-1 cells**

[0268] Human acute monocytic leukemia cell line THP1 (ATCC) was cultured in RPMI1640/GLUTAMAX (Invitrogen) + 10% Foetal Bovine Serum (Invitrogen) + Pen/Strep. and maintained between $2-9 \times 10^5$ cells/ml.

[0269] Cells were harvested from culture and prepared as a single cell suspension. $0.3-0.4 \times 10^6$ cells/sample were then distributed in 96-well round-bottom tissue culture plates (Costar. Cambridge, MA) and washed 1X with cold FACS buffer.

[0270] After centrifugation at $3.50 \times g$ for 5 min., supernatant is discarded and plates put on ice. Binding of IgG to Fc γ Rs on THP-1 cells was performed by incubating monomeric IgGs in FACS Buffer starting from 30 μ g/ml to 0.02 μ g/ml (dilutions 1:3) in a total volume of 100 μ l at 4 °C for 30 min.

[0271] Cells were then washed three times with 200 μ l of FACS buffer, and IgG binding detection is achieved by adding 100 μ l of Donkey anti Human IgG (H+L) R-Phycoerythrin conjugated (Jackson Immuno Research cat.# 709-116-149) 1:100 in FACS buffer. After gentle vortexing, cells were incubated at 4°C for 30 min.

[0272] Plates were washed 2X with 200 μ l of FACS buffer, cells are finally resuspended and transferred in 0.5 ml of FACS Buffer and acquired by using a flow cytometer.

Results

[0273] Figure 10 clearly shows that as expected based on prior art disclosures (see US Patent 5,624,821 Winter) the mutated isoform BXhVH5VL1 N297A is devoid of significant binding capability to cellular Fc receptors.

Example 7**In vivo Experiments**

[0274] In vivo experiments that were performed to further assay the antibodies/derivatives of the present invention are set out below;

NGF-mediated pain models

[0275] Nerve growth factor (NGF) and its receptor TrkA are crucial mediators of the pain sensations characteristic of inflammatory pain.

[0276] Classically, NGF is known as a developmental survival factor for sensory and sympathetic neurons but it continues to be synthesized in adult animals in the periphery, where it is transported retrogradely to the cell bodies of sensory neurons (Hendry et al., 1974, Otten et al 1980).

[0277] Inflammation and nerve injury cause the release of NGF which stimulates primary afferent fibres and induces behavioural sensitisation. Subcutaneous chronic treatment with NGF in rats causes hyperalgesia and alters local cutaneous sensation (Lewin et al., 1993; Andreev et al., 1995).

[0278] Intradermal injection of rhNGF into human forearm and masseter muscle in humans causes hyperalgesia, allodynia and alters local cutaneous sensation that began 3hrs following injection and peaked 1-7 days post injection and recovered by day 21 (Dyck et al., 1997; Svensson et al., 2003).

[0279] Thus, injections of rhNGF into the rat hindpaw were used here as a model of behavioural sensitisation that was specifically generated by NGF.

[0280] The present experiments involved two different protocols:

1. We first examined whether intradermal injection of recombinant human (rh) NGF alone in rat paw could cause behavioural sensitisation as measured by standard nociceptive tests for hyperalgesia (Hargreave's plantar test). We then established whether intradermal co-injection of the murine IgG, muMNACEP, human IgG, and BXhVH5VL1 N297A antibodies at a dose of 100µg could affect the rhNGF-induced sensitisation. Murine IgG₁ and human IgG antibodies were used as a negative controls at the appropriated dosages.

2. We then established whether systemic pre-treatment of muMNACEP antibody (at doses of 8 and 1 mg/Kg, i.p.) and BXhVH5VL1 N297A (doses of 8, 3, and 1 mg/Kg, i.p.) could affect the peripherally induced rhNGF sensitisation.

[0281] In the first protocol, whereby treatments were administered locally, male Lewis rats (Charles River, 5-6weeks 200g) were used with 8-9 animals per group and 4 experimental groups, injected according to the set method. Injections were carried out blind. A summary of the treatments is outlined in the table below.

	muMNACEP /BXhVH5VL1 N297A	mIgG ₁ /hIgG
Intradermal treatments	100µg + 500ng rhNGF, n=9	100µg + 500ng rhNGF, n=9

[0282] In the second protocol, whereby treatments were administered systemically (i.p.) 24hrs prior to rhNGF paw injection, male Lewis rats (Charles River, 5-6weeks 200 g) were used with 10-12 animals per group and 10 experimental groups. Injections were carried out blind. A summary of the treatments is outlined in the table below.

	muMNACEP	mIgG ₁	BXhVH5VL1 N297A	hIgG
Systemic i.p. 24hr pretreatments	1mg/Kg n=10 8mg/Kg n= 10	1mg/Kg n=12 8mg/Kg n= 8	1mg/Kg n=10 3mg/Kg n=10 8mg/Kg n= 12	1mg/Kg n=10 3mg/Kg n=10 8mg/Kg n= 12
rhNGF intradermal	500ng	500ng	500ng	500ng

Assay

[0283] All animals were numbered and then habituated to behaviour- testing procedures 24-48hr prior to commencement of the experiment. Behaviour readouts were the paw withdrawal latency to the plantar test as a measure of hyperalgesia.

[0284] Baseline recordings were taken to establish paw withdrawal latencies. Nociceptive sensitivity was induced by intradermal rhNGF injected at Time point 0 and behavioural nociceptive sensitivity was monitored 30 minutes, 1 hour, 2 hours, 24 hours and 48 hours following rhNGF injection. Treatments were administered blind as follows:

Protocol 1: Treatment administration by intradermal injection at Time 0.

Protocol 2: Treatment administration by systemic single injection IP 24h before rhNGF paw injection.

[0285] Baseline plantar and von Frey tests were performed before drug treatments were administered.

[0286] Hyperalgesia measurements were taken 30min, 1hr, 2hrs, 24hrs and 48hrs after rhNGF injection. Three to four recordings were taken for each hindpaw ipsilateral (right paw, rhNGF-injected) and contralateral (left paw, un-injected) to rhNGF injection.

[0287] Data from animals from individual treatment groups were collated, and means and standard deviations were calculated for the contralateral and ipsilateral paw responses. The presence of hyperalgesia was indicated by a significant reduction in the paw withdrawal latency (recorded in seconds) in the rhNGF-injected ipsilateral hindpaw when compared with the control contralateral paw (by paired t-test) and when compared with the pre-injection/pre-treatment baseline (by one-way ANOVA).

Intradermal anti-hyperalgesic efficacy

[0288] We compared the anti-hyperalgesic efficacy of BXhVH5VL1 N297A (Figure 11) and muMNACEP (Figure 12) (plus mlgG₁ and hlgG as relative controls) by intradermal injection in this model of NGF-induced hyperalgesia.

[0289] When BXhVH5VL1 N297A and muMNACEP were co-injected with rhNGF, there was no significant development of hyperalgesia, as indicated by no significant difference between ipsilateral and contralateral paw withdrawal responses (Figures 11 and 12).

[0290] Hyperalgesia in ipsilateral paw responses were always present following co-injection with the negative controls (mlgG₁, hlgG).

[0291] Data are represented as means \pm 95% CI, before (baseline) and following intradermal injection of 500ng rhNGF with respective treatments (at arrow). Significant reduction in paw withdrawal latency ipsilateral is indicated by '**' '***' ($p < 0.05$, $p < 0.01$, paired t-test) when compared to the contralateral paw withdrawal.

Systemic anti-hyperalgesic efficacy

[0292] We compared the anti-hyperalgesic efficacy of BXhVH5VL1 N297A, muMNACEP mlgG₁, and hlgG by systemic injection in this model of NGF-induced hyperalgesia.

[0293] Three different doses of BXhVH5VL1 N297A and control hlgG (1, 3, and 8 mg/Kg) were tested (Figure 13). Similarly, two different doses of muMNACEP and mlgG₁ were tested, 1mg/Kg and 8mg/Kg (Figure 14). All treatments were administered i.p. 24hours prior to intradermal injection with rhNGF.

[0294] Systemic pre-treatment of 8 and 3 mg/kg BXhVH5VL1 N297A significantly prevented the development of hyperalgesia following rhNGF injection, as indicated by no significant difference between ipsilateral and contralateral paw withdrawal responses (Figure 13).

[0295] Systemic pre-treatment with the murine parental antibody mMNACEP (8 mg/Kg) also prevented the development of rhNGF-induced hyperalgesia (Figure 14). However, the overall analgesic response of BXhVH5VL1 N297A appeared to be better as compared with mMNACEP antibody.

[0296] At the same dose, hyperalgesia in ipsilateral paw responses was always present following co-injection with the negative control mlgG₁ and hlgG.

[0297] Data are represented as means \pm 95% CI, before (baseline) and following intradermal injection of 500ng rhNGF with respective treatments (at arrow). Significant reduction in paw withdrawal latency ipsilateral is indicated by '**' '***' ($p < 0.05$, $p < 0.01$, paired t-test) when compared to the contralateral paw withdrawal.

Example 8

[0298] Further in vivo experiments that may be performed to further assay the antibodies/derivatives of the present invention are set out below:

Formalin test

[0299] Mice are pretreated with the antibody/derivative intraperitoneally and 18 hours later are injected in the right dorsal footpad with 5% Formalin. Licking time (time spent licking the injured paw) is measured for up to 1 hour.

Chronic constriction injury test

[0300] Mice are subject to surgical constriction of sciatic nerve, in order to induce a neuropathic allodynia. Animals are then treated with antibody/derivative and withdrawal response to a mechanical stimulus localized to the injured limb

versus the contralateral limb is measured.

Arthritis model

5 **[0301]** Rats are injected with complete Freund's adjuvant at the tail base intradermally. Approximately three weeks late they develop a systemic poly arthritis characterized by joint pain. Animals are treated with the antibody/derivative and the analgesic effect is evaluated by the vocalization assay consisting of measurement of intensity of vocalization upon gentle manipulation of the joints.

10 **Monkey carrageenan induced pain model**

[0302] Rhesus macaques are pretreated intravenously with the antibody/derivative. The following day, animals are injected subcutaneously with carrageenan in the tail. Withdrawal time from a heat stimulus is measured.

15 **General Points**

[0303] Unless the context indicates otherwise, the following general points apply:

20 The term "comprises" is non-limiting in that it covers "including" as well as "consisting of". Thus the word 'comprises' and variations such as 'comprise' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

SEQUENCE LISTING

25

[0304]

<110> Lay Line Genomics SPA

30

<120> ANTI-TRKA ANTIBODIES AND DERIVATIVES THEREOF

<130> 17539EP

35

<160> 5

<170> PatentIn version 3.3

40

<210> 1

<211> 123

<212> PRT

<213> Homo sapiens

<400> 1

45

50

55

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30

Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Ala Met Tyr Gly Asn Asp Phe Phe Tyr Pro Met Asp Tyr
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 2

<211> 123

<212> PRT

<213> Homo sapiens

<400> 2

Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val
50 55 60

5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

10 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Ala Met Tyr Gly Asn Asp Phe Phe Tyr Pro Met Asp Tyr
100 105 110

15 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 3

<211> 123

20 <212> PRT

<213> Homo sapiens

<400> 3

25 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

30 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Gly Lys Arg Leu Glu Trp Val
35 40 45

35 Ala Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val
50 55 60

40 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

45 Ala Lys Gly Ala Met Tyr Gly Asn Asp Phe Phe Tyr Pro Met Asp Tyr
100 105 110

50 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 4

<211> 123

<212> PRT

<213> Homo sapiens

55 <400> 4

1 Glu Val Gln Leu ₅ Leu Glu Ser Gly Gly ₁₀ Gly Leu Val Gln Pro Gly Gly ₁₅
 5 Ser Leu Arg ₂₀ Leu Ser Cys Ala Ala ₂₅ Ser Gly Phe Thr Phe ₃₀ Ser Thr Tyr
 10 Thr Met ₃₅ Ser Trp Val Arg Gln Ala ₄₀ Pro Gly Lys Arg ₄₅ Leu Glu Trp Val
 15 Ala Tyr ₅₀ Ile Ser Lys Gly ₅₅ Gly Gly Ser Thr Tyr ₆₀ Tyr Pro Asp Thr Val
 20 Lys Gly Arg Phe Thr ₇₀ Ile Ser Arg Asp Asn ₇₅ Ser Lys Asn Thr Leu Tyr ₈₀
 25 Leu Gln Met Asn ₈₅ Ser Leu Arg Ala Glu ₉₀ Asp Thr Ala Val Tyr ₉₅ Tyr Cys
 30 Ala Arg Gly Ala ₁₀₀ Met Tyr Gly Asn ₁₀₅ Asp Phe Phe Tyr Pro ₁₁₀ Met Asp Tyr
 35 Trp Gly Gln ₁₁₅ Gly Thr Thr Val ₁₂₀ Thr Val Ser Ser

<210> 5
 <211> 123
 <212> PRT
 <213> Homo sapiens
 <400> 5

1 Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 10 Thr Met Ser Trp Val Arg Gln Thr Pro Gly Lys Arg Leu Glu Trp Val
 15 Ala Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val
 20 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 25 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 30 Ala Arg Gly Ala Met Tyr Gly Asn Asp Phe Phe Tyr Pro Met Asp Tyr
 35 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115

120

30 <210> 6
 <211> 123
 <212> PRT
 <213> Homo sapiens

35 <400> 6

40

45

50

55

EP 2 252 633 B9

	Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	
				20					25					30			
	Thr	Met	Ser	Trp	Ala	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
10			35				40						45				
	Ala	Tyr	Ile	Ser	Lys	Gly	Gly	Gly	Ser	Thr	Tyr	Tyr	Pro	Asp	Thr	Val	
	50					55						60					
15	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70				75					80		
	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	
20				85						90					95		
	Ala	Arg	Gly	Ala	Met	Tyr	Gly	Asn	Asp	Phe	Phe	Tyr	Pro	Met	Asp	Tyr	
				100					105					110			
25	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser						
			115					120									

<210> 7
 <211> 106
 <212> PRT
 <213> Homo sapiens
 <400> 7

EP 2 252 633 B9

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr
35 40 45

Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
65 70 75 80

Asp Phe Ala Val Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 8
<211> 106
<212> PRT
<213> Homo sapiens

<400> 8

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr
35 40 45

Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
65 70 75 80

Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 9

EP 2 252 633 B9

<211> 106
<212> PRT
<213> Homo sapiens

5 <400> 9

10
15
20
25
30
Gln Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr
35 40 45
Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Phe Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
65 70 75 80
Asp Phe Ala Val Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

35 <210> 10
<211> 106
<212> PRT
<213> Homo sapiens

<400> 10

40
45
50
55
Gln Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr
35 40 45
Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
65 70 75 80
Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr

85

90

95

5 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 11

<211> 106

<212> PRT

10 <213> Homo sapiens

<400> 11

15 Gln Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr
35 40 45

25 Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
30 65 70 75 80

Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95

35 Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 12

40 <211> 106

<212> PRT

<213> Homo sapiens

<400> 12

45 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Glu Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
50 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr
55 35 40 45

Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60

EP 2 252 633 B9

	Gly	Ser	Gly	Thr	Phe	Tyr	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro	Glu	
	65					70					75					80	
5	Asp	Ala	Ala	Asp	Tyr	Tyr	Cys	His	Gln	Trp	Ser	Ser	Tyr	Pro	Trp	Thr	
					85					90					95		
10	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys							
				100					105								
	<210> 13																
	<211> 106																
	<212> PRT																
15	<213> Homo sapiens																
	<400> 13																
20	Gln	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly	
	1				5					10					15		
	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Ser	Ala	Ser	Ser	Ser	Val	Ser	Tyr	Met	
25				20					25					30			
	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ser	Pro	Arg	Leu	Leu	Ile	Tyr	
			35					40					45				
30	Thr	Thr	Ser	Asn	Leu	Ala	Ser	Gly	Ile	Pro	Ser	Arg	Phe	Ser	Gly	Ser	
	50						55					60					
	Gly	Ser	Gly	Thr	Phe	Tyr	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro	Glu	
35	65					70					75					80	
	Asp	Ala	Ala	Asp	Tyr	Tyr	Cys	His	Gln	Trp	Ser	Ser	Tyr	Pro	Trp	Thr	
					85					90					95		
40	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys							
				100					105								
	<210> 14																
45	<211> 106																
	<212> PRT																
	<213> Homo sapiens																
	<400> 14																
50																	
55																	

EP 2 252 633 B9

Gln Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Glu Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Arg Leu Leu Ile Tyr

35 40 45

Thr Thr Ser Asn Leu Ala Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Phe Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu
65 70 75 80

Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 15

<211> 123

<212> PRT

<213> Mus musculus

<400> 15

EP 2 252 633 B9

Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

5 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30

10 Thr Met Ser Trp Ala Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
35 40 45

Ala Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val
50 55 60

15 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

20 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

Ala Arg Gly Ala Met Tyr Gly Asn Asp Phe Phe Tyr Pro Met Asp Tyr
100 105 110

25 Trp Gly Gln Gln Thr Ser Val Thr Val Ser Ser
115 120

<210> 16

30 <211> 106

<212> PRT

<213> Mus musculus

<400> 16

35

40

45

50

55

EP 2 252 633 B9

	Asp	Ile	Val	Leu	Ser	Gln	Ser	Pro	Ala	Ile	Met	Ser	Ala	Ser	Leu	Gly	
	1				5					10					15		
5	Glu	Glu	Ile	Thr	Leu	Thr	Cys	Ser	Ala	Ser	Ser	Ser	Val	Ser	Tyr	Met	
				20					25					30			
	His	Trp	Tyr	Gln	Gln	Lys	Ser	Gly	Thr	Ser	Pro	Lys	Leu	Leu	Ile	Thr	
10			35					40					45				
	Thr	Thr	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	
		50					55					60					
15	Gly	Ser	Gly	Thr	Phe	Tyr	Ser	Leu	Thr	Ile	Ser	Ser	Val	Glu	Ala	Glu	
	65					70					75					80	
	Asp	Ala	Ala	Asp	Tyr	Tyr	Cys	His	Gln	Trp	Ser	Ser	Tyr	Pro	Trp	Thr	
20					85					90					95		
	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys							
				100						105							
25																	
	<210> 17																
	<211> 123																
	<212> PRT																
	<213> Homo sapiens																
30																	
	<400> 17																
35	Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	
				20					25					30			
40	Thr	Met	Ser	Trp	Ala	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35				40						45				
	Ala	Tyr	Ile	Ser	Lys	Gly	Gly	Gly	Ser	Thr	Tyr	Tyr	Pro	Asp	Thr	Val	
45		50					55					60					
	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70				75					80		
50	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys	
				85					90					95			
55	Ala	Arg	Gly	Ala	Met	Phe	Gly	Asn	Asp	Phe	Phe	Phe	Pro	Met	Asp	Arg	
				100					105					110			

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

5 <210> 18
<211> 106
<212> PRT
<213> Homo sapiens

10 <400> 18

Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

20 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile Tyr
35 40 45

25 Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
65 70 75 80

30 Asp Val Ala Thr Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Trp Thr
85 90 95

35 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 19
<211> 98
<212> PRT
40 <213> Homo sapiens

<400> 19

45

50

55

EP 2 252 633 B9

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

10 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

15 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

20 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys

25 <210> 20
<211> 15
<212> PRT
<213> Homo sapiens

30 <400> 20

Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10 15

35 <210> 21
<211> 95
<212> PRT
<213> Homo sapiens

40 <400> 21

45

50

55

EP 2 252 633 B9

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

5 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

10

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

¹⁵

Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro
65					70					75					80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro

85 90 95

<210> 22

<211> 12

<212> PRT

25 <213> Homo sapiens

<400> 22

30 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> 23

<211> 453

<212> PRT

35 <213> Homo sapiens

<400> 23

40

45

50

55

EP 2 252 633 B9

	Glu	Val	Lys	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	
				20					25					30			
	Thr	Met	Ser	Trp	Val	Arg	Gln	Thr	Pro	Gly	Lys	Arg	Leu	Glu	Trp	Val	
10			35					40					45				
	Ala	Tyr	Ile	Ser	Lys	Gly	Gly	Gly	Ser	Thr	Tyr	Tyr	Pro	Asp	Thr	Val	
		50					55					60					
15	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70					75					80	
	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
20				85						90					95		
	Ala	Arg	Gly	Ala	Met	Tyr	Gly	Asn	Asp	Phe	Phe	Tyr	Pro	Met	Asp	Tyr	
				100					105					110			
25	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	
			115					120					125				
	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	
30			130				135					140					
	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	
35						150					155					160	
	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	
					165					170					175		
40	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	
				180					185					190			
	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	
45			195					200					205				
	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	
		210					215					220					
50	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
	225					230					235					240	

55

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 245 250 255
 5 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 260 265 270
 10 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 275 280 285
 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser
 290 295 300
 15 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 305 310 315 320
 20 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 325 330 335
 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 340 345 350
 25 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 355 360 365
 30 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 370 375 380
 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 385 390 395 400
 35 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 405 410 415
 40 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 420 425 430
 Val Met His Glu Gly Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 435 440 445
 45 Leu Ser Pro Gly Lys
 450

Claims

1. An anti-TrkA antibody that comprises:

one of the following combinations of light and heavy chains: SEQ ID NO: 3 and SEQ ID NO: 9, SEQ ID NO: 5 and SEQ ID NO: 7, or SEQ ID NO: 5 and SEQ ID NO: 9.

2. An antibody according to claim 1 that binds with greater affinity to TrkA than to Trk B.

3. An antibody according to any preceding claim that is capable of blocking or reducing the binding of NGF to the TrkA receptor.
- 5 4. An antibody according to any preceding claim that is capable of blocking or reducing one or more biological activities that would otherwise be induced by the binding of NGF to the TrkA receptor.
5. An antibody according to any preceding claim comprising a non-rodent derived constant region.
- 10 6. An antibody according to any preceding claim comprising a human constant region or a constant region with at least 75% sequence identity with a human constant region.
7. An antibody according to any preceding claim comprising a human IgG constant region or a constant region with at least 75% sequence identity therewith.
- 15 8. An antibody according to any preceding claim comprising a constant region that has one or more amino acid changes relative to a human immunoglobulin constant region that prevent/reduce one or more of the following,
 - a) activation of complement
 - b) complement-mediated lysis
 - 20 c) activation of T cells
 - d) binding to an Fc receptor.
9. An antibody according to any preceding claim that provides an OD_{450/630} nm value of greater than 0.1 in a TrkA-IgG ELISA binding assay.
- 25 10. An antibody according to any preceding claim that provides an increase in FACS staining of TF1 cells in a FACS based cellular binding assay of TrkA surface expression on TF1 cells that is an increase of over 1.0 fold.
- 30 11. An antibody according to any preceding claim that has a K_D value of less than 4.18×10^{-8} M in respect of TrkA-IgG binding in a surface plasmon resonance analysis assay wherein TrkA-IgG is immobilized on a CM-5 sensor chip.
12. An antibody according to any preceding claim that has at least 90% humanisation when measured over the total framework regions of the variable region of at least one chain.
- 35 13. An antibody according to any preceding claim that has at least 95% humanisation when measured over the total framework regions of the variable region of at least one chain.
14. An antibody according to any of claims 12 to 13 that has at least the percentage humanisation given in any of said claims in respect of the framework regions for both the light and heavy chains.
- 40 15. A derivative of an antibody according to any preceding claim wherein the derivative is
 - a) a fragment of said antibody, wherein the fragment is in the form of ScFv chains, is a Fv or Fab fragment
 - b) a fragment multimer such as minibodies, bis(or higher)-ScFv, diabodies, triabodies, tetrabodies, Fab mul-
 - 45 timers,
 - c) a fusion product of said antibody fragment or fragment multimer and another moiety.
16. A derivative according to claim 15 wherein the derivative is a fusion product and another moiety is an agent selected from the following: a diagnostic agent, a therapeutic agent, a marking agent, an agent that increases the half life and/or that reduces the immunogenicity of said derivative in a human host.
- 50 17. A derivative thereof according to claim 16 wherein the therapeutic agent is a cytotoxin.
18. An antibody or derivative thereof according to any preceding claim that is PEGylated.
- 55 19. An antibody or derivative according to any preceding claim in immobilised form.
20. An antibody or derivative according to any of claims 1 to 19, for use in medicine

21. An antibody or derivative according to any of claims 1 to 19, for use in the treatment of pain.

22. An antibody or derivative according to any of claims 1 to 19, for use in the treatment of chronic pain.

5 23. An antibody or derivative according to any of claims 1 to 19, for use in the treatment of acute pain.

24. An antibody or derivative according to any of claims 1 to 19, for use in the treatment of pain associated with one or more of the following: pancreatitis, kidney stones, endometriosis, IBD, Crohn's disease, post surgical adhesions, gall bladder stones, headaches, dysmenorrhea, musculoskeletal pain, sprains, visceral pain, ovarian cysts, prostatitis, cystitis, interstitial cystitis, post-operative pain, migraine, trigeminal neuralgia, pain from burns and/or wounds, pain associated with trauma, neuropathic pain, pain associated with musculoskeletal diseases, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, periarticular pathologies, oncological pain, pain from bone metastases, HIV infection.

15 25. An antibody or derivative according to any of claims 1 to 19, for use in the treatment of cancer, a neuronal disorder (e.g. a neurodegenerative disorder), Alzheimer's disease, diabetes mellitus, a viral disorder, an HIV mediated disorder, leprosy, or an inflammatory disorder.

20 26. An antibody or derivative for use according to any of claims 21 to 25, whereas the treatment involves ADCC.

27. A combination of an antibody or derivative according to any of claims 1 to 19 and an analgesic, for simultaneous, sequential or concerted administration in medicine.

25 28. A combination of an antibody or derivative according to any of claims 1 to 19 and NGF, for simultaneous, sequential or concerted administration in medicine.

29. A combination of an antibody or derivative according to any of claims 1 to 19 and a further anti-TrkA antibody or derivative thereof, for simultaneous, sequential or concerted administration in medicine.

30 30. A pharmaceutical composition comprising an antibody or derivative thereof according to any of claims 1 to 19 and a pharmaceutically acceptable carrier or excipient.

31. A pharmaceutical composition comprising an antibody according to any of claims 1 to 19 and another pharmaceutically active agent.

35 32. A pharmaceutical composition according to claim 31 wherein said another agent is one or more of:

- a) an analgesic agent
- b) another anti-TrkA antibody or derivative thereof
- c) NGF
- d) an anti-cancer agent.

33. An antibody or derivative thereof according to any of claims 1 to 19 for use in diagnosis or prognosis.

45 34. An antibody or derivative thereof for use in the diagnosis or prognosis of any of the diseases or disorders specified in claims 21 to 25.

35. A nucleic acid encoding an antibody or derivative thereof according to any of claims 1 to 19.

50 36. A vector comprising a nucleic acid according to claim 35.

37. A non-human transgenic mammal that expresses an antibody or derivative thereof according to any of claims 1 to 19, or that can be induced to provide such expression.

55 38. A kit of parts comprising an antibody or derivative according to any one of claims 1 to 19 together with instructions directing the use thereof by a subject as an analgesic.

Patentansprüche

1. Ein anti-TrkA Antikörper, der eine der folgenden Kombinationen von leichten und schweren Ketten umfasst: SEQ ID NO: 3 und SEQ ID NO: 9, SEQ ID NO: 5 und SEQ ID NO: 7, oder SEQ ID NO: 5 und SEQ ID NO: 9.
2. Ein Antikörper gemäß Anspruch 1, der TrkA mit einer grösseren Affinität als TrkB bindet.
3. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der in der Lage ist, die Bindung von NGF an den TrkA Rezeptor zu blockieren oder zu reduzieren.
4. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der in der Lage ist, eine oder mehrere biologische Aktivitäten zu blockieren oder zu reduzieren, die sonst durch die Bindung von NGF an den TrkA Rezeptor induziert würden.
5. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, umfassend eine konstante Region abgeleitet von einem Nicht-Nagetier.
6. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, umfassend eine humane konstante Region oder eine konstante Region mit wenigstens 75-prozentige Sequenzidentität mit einer humanen konstanten Region.
7. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, umfassend eine humane IgG konstante Region oder eine konstante Region mit wenigstens 75-prozentige Sequenzidentität damit.
8. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, umfassend eine konstante Region, die eine oder mehrere Änderungen der Aminosäuren im Verhältnis zu einer konstanten Region eines humanen Immunglobulins aufweist, die eines oder mehr des Folgenden verhindert/reduziert:
 - a) Komplementaktivierung
 - b) Komplement-vermittelte Lyse
 - c) T-Zell Aktivierung
 - d) Bindung an Fc-Rezeptor.
9. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der einen OD450/630nm Wert von grösser 0.1 in einem TrkA-IgG ELISA Bindungstest liefert.
10. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der eine Zunahme der FACS-Färbung von TF1 Zellen in einem FACS basierten zellulären Bindungstest der TRKA Oberflächenexpression auf TF1 Zellen liefert, wobei die Zunahme mehr als ein 1.0-fach ist.
11. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der einen K_D -Wert von weniger als 4.18×10^{-8} M hat in Bezug auf die Bindung TrkA-IgG in einem Oberflächen-Plasmon-Resonanz (SPR) Analysetest, bei dem TrkA-IgG auf einem CM-5 Sensorchip immobilisiert ist.
12. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der, wenn gemessen über die gesamte Gerüstregion (framework region) der variablen Region wenigstens einer Kette, mindestens eine 90-prozentige Humanisierung aufweist.
13. Ein Antikörper gemäß einem der vorhergehenden Ansprüche, der, wenn gemessen über die gesamte Gerüstregion (framework region) der variablen Region wenigstens einer Kette, mindestens eine 95-prozentige Humanisierung aufweist.
14. Ein Antikörper gemäß einem der Ansprüche 12 bis 13, der wenigstens den Prozentsatz an Humanisierung hat, der in einem der beiden Ansprüche gegeben ist in Bezug auf die Gerüstregionen (framework regions) von beiden, der leichten und der schweren Kette.
15. Ein Derivat eines Antikörpers gemäß einem der vorhergehenden Ansprüche, worin das Derivat ist
 - a) ein Fragment des besagten Antikörpers, worin das Fragment in der Form von ScFv Ketten vorliegt, ein Fv

oder Fab Fragment ist,

b) ein Fragmentmultimer wie Minibodies, zwei (oder mehrere) ScFvs, diabodies, triabodies, tetrabodies, Fab-Multimere,

c) ein Fusionsprodukt des besagten Antikörperfragments oder Fragmentmultimers und einem anderen Teil ist.

5 16. Ein Derivat gemäss Anspruch 15, worin das Derivat ein Fusionsprodukt ist und der andere Teil ein Agens ist, ausgewählt aus dem Folgenden: ein diagnostisches Agens, ein therapeutisches Agens, ein markierendes Agens, ein Agens, welches die Halbwertszeit des Derivats erhöht und/oder welches die Immunogenizität des Derivats in einem humanen Wirt erhöht.

10 17. Ein Derivat davon gemäss Anspruch 16, worin das therapeutische Agens ein Zytotoxin ist.

18. Ein Antikörper oder ein Derivat gemäss einem der vorhergehenden Ansprüche der oder das pegyliert ist.

15 19. Ein Antikörper oder ein Derivat gemäss einem der vorhergehenden Ansprüche in immobilisierter Form.

20 20. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur medizinischen Verwendung.

21. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur Verwendung bei der Behandlung von Schmerz.

22. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur Verwendung bei der Behandlung von chronischem Schmerz.

25 23. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur Verwendung bei der Behandlung von akutem Schmerz.

30 24. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur Verwendung bei der Behandlung von Schmerz verbunden mit einem oder mehreren des Folgenden: Pancreatitis, Nierensteine, Endometriose, entzündliche Darmerkrankung (IBD), Crohnsche Krankheit, postchirurgische Adhäsivprozesse, Gallenblasensteine, Kopfweh, Dysmenorrhoe, muskuloskelettale Schmerzen, Verstauchungen, Eingeweideschmerzen, ovarielle Zysten, Prostatitis, Cystitis, interstitielle Cystitis, postoperative Schmerzen, Migräne, Trigeminusneuralgie, Schmerzen von Verbrennungen und/oder Wunden, Schmerzen in Verbindung mit Traumata, neuropathische Schmerzen, Schmerzen in Verbindung mit muskuloskelettalen Krankheiten, rheumatoide Arthritis, Osteoarthritis, Spondylitis ankylosans, periartikuläre Pathologien, onkologische Schmerzen, durch Knochenmetastasen verursachte Schmerzen, HIV Infektionen.

35 25. Ein Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19 zur Verwendung bei der Behandlung von Krebs, einer neuronalen Störung (bspw. einer neuro-degenerativen Störung), Alzheimer, Diabetes mellitus, einer viralen Störung, einer durch HIV verursachten Störung, Lepra oder einer entzündlichen Störung.

40 26. Ein Antikörper oder ein Derivat zur Verwendung gemäss einem der Ansprüche 21 bis 25, wobei die Behandlung antikörperabhängige zellvermittelte Zytotoxizität (ADCC) involviert.

45 27. Eine Kombination eines Antikörpers oder eines Derivats gemäss einem der Ansprüche 1 bis 19 und eines Analgetikums zur simultanen, sequenziellen oder konzertierten Verabreichung in der Medizin.

50 28. Eine Kombination eines Antikörpers oder eines Derivats gemäss einem der Ansprüche 1 bis 19 und NGF zur simultanen, sequenziellen oder konzertierten Verabreichung in der Medizin.

29. Eine Kombination eines Antikörpers oder eines Derivats gemäss einem der Ansprüche 1 bis 19 und eines weiteren anti-TrkA Antikörpers oder eines Derivats davon, zur simultanen, sequenziellen oder konzertierten Verabreichung in der Medizin.

55 30. Eine pharmazeutische Zusammensetzung umfassend einen Antikörper oder ein Derivat davon gemäss einem der Ansprüche 1 bis 19 und einen pharmazeutisch akzeptablen Träger oder Hilfsstoff.

31. Eine pharmazeutische Zusammensetzung umfassend einen Antikörper gemäss einem der Ansprüche 1 bis 19

und ein anderes pharmazeutisch aktives Agens.

32. Eine pharmazeutische Zusammensetzung gemäss Anspruch 31, worin besagtes Agens eines oder mehrere ist von:

- a) einem analgesischen Agens
- b) einem anderen anti-TrkA Antikörper oder einem Derivat davon
- c) NGF
- d) einem Anti-Krebs Agens.

33. Ein Antikörper oder ein Derivat davon gemäss einem der Ansprüche 1 bis 19, zur Verwendung in der Diagnose oder Prognose.

34. Ein Antikörper oder ein Derivat davon zur Verwendung in der Diagnose oder Prognose einer der in den Ansprüchen 21 bis 25 aufgeführten Krankheiten oder Störungen.

35. Eine Nukleinsäure kodierend einen Antikörper oder ein Derivat davon gemäss einem der Ansprüche 1 bis 19.

36. Ein Vektor umfassend die Nukleinsäure gemäss Anspruch 35.

37. Ein non-humanes transgenes Säugetier, welches einen Antikörper oder ein Derivat davon gemäss einem der Ansprüche 1 bis 19 exprimiert, oder welches zu solch einer Expression induziert werden kann.

38. Ein Kit umfassend einen Antikörper oder ein Derivat gemäss einem der Ansprüche 1 bis 19, zusammen mit Instruktionen, welche seine Verwendung als Analgetikum durch einen Patienten beschreiben.

Revendications

1. Un anticorps anti-TrkA comprenant: une parmi les combinaisons suivantes de chaînes légères et lourdes: SEQ ID n° 3 et SEQ ID n° 9, SEQ ID n° 5 et SEQ ID n° 7, ou SEQ ID n° 5 et SEQ ID n° 9.

2. Un anticorps selon la revendication 1 qui se lie avec une affinité supérieure à TrkA qu'à TrkB.

3. Un anticorps selon l'une quelconque des revendications précédentes, qui est capable de bloquer ou de réduire la liaison du facteur de croissance du tissu nerveux (NGF) au récepteur TrkA.

4. Un anticorps selon l'une quelconque des revendications précédentes, qui est capable de bloquer ou de réduire une ou plusieurs activités biologiques qui autrement pourraient être induites par la liaison du NGF au récepteur TrkA.

5. Un anticorps selon l'une quelconque des revendications précédentes, comprenant une région constante dérivée de non-rongeurs.

6. Un anticorps selon l'une quelconque des revendications précédentes, comprenant une région constante humaine ou une région constante avec au moins 75% d'identité de séquence avec une région constante humaine.

7. Un anticorps selon l'une quelconque des revendications précédentes, comprenant une région constante d'immunoglobuline G (IgG) humaine ou une région constante avec au moins 75% d'identité de séquence avec celle-ci.

8. Un anticorps selon l'une quelconque des revendications précédentes, comprenant une région constante avec un ou plusieurs changements d'acides aminés par rapport à une région constante d'immunoglobuline humaine qui prévient/réduit une ou plusieurs parmi les suivantes:

- a) activation du complément
- b) lyse à médiation complémentaire
- c) activation de cellules T
- d) liaison à un récepteur Fc.

9. Un anticorps selon l'une quelconque des revendications précédentes, qui fournit une valeur de densité optique

OD450/630 nm supérieure à 0.1 dans un test de liaison ELISA TrkA-IgG.

- 5 10. Un anticorps selon l'une quelconque des revendications précédentes, qui procure une augmentation de la coloration de cellules TF 1 telle que déterminée par trieur de cellules à fluorescence (FACS) dans un test de liaison cellulaire basé sur un FACS d'une surface d'expression TrkA sur des cellules TF 1 qui constitue une augmentation supérieure à 1.0 fois.
- 10 11. Un anticorps selon l'une quelconque des revendications précédentes, qui possède une valeur K_D de moins de 4.18×10^{-8} M par rapport à la liaison TrkA-IgG dans un test d'analyse par résonance de plasmon en surface (SPR), dans lequel TrkA-IgG est immobilisé sur une puce de capteur CM-5.
- 15 12. Un anticorps selon l'une quelconque des revendications précédentes, qui est humanisé à 90% au moins lorsque mesuré sur la totalité des régions cadres de la région variable d'au moins une chaîne.
- 20 13. Un anticorps selon l'une quelconque des revendications précédentes, qui est humanisé à 95% au moins lorsque mesuré sur la totalité des régions cadres de la région variable d'au moins une chaîne.
- 25 14. Un anticorps selon l'une quelconque des revendications 12 à 13, qui est humanisé au moins au pourcentage indiqué dans l'une quelconque desdites revendications par rapport aux régions cadres tant pour les chaînes légères que pour les chaînes lourdes.
- 30 15. Un dérivé d'un anticorps selon l'une quelconque des revendications précédentes, dans lequel le dérivé est
 - a) un fragment dudit anticorps, dans lequel le fragment est en la forme de chaînes monocaténaires ScFv, est un fragment variable Fv ou fragment de liaison à l'antigène Fab,
 - b) un multimère de fragment tel que minicorps, ScFv bispécifiques ou plus, diacorps, triacorps, tetracorps, multimères de Fab,
 - c) un produit de fusion dudit fragment d'anticorps ou multimère de fragment et un autre fragment.
- 35 16. Un dérivé selon la revendication 15, dans lequel le dérivé est un produit de fusion et l'autre fragment est un agent sélectionné parmi ce qui suit: un agent diagnostique, un agent thérapeutique, un agent de marquage, un agent qui augmente la demi-vie et/ou qui réduit l'immunogénicité dudit dérivatif dans un hôte humain.
- 40 17. Un dérivé de celui-ci selon la revendication 16, dans lequel l'agent thérapeutique est une cytotoxine.
- 45 18. Un anticorps ou son dérivé selon l'une quelconque des revendications précédentes qui est pégylé.
19. Un anticorps ou dérivé selon l'une quelconque des revendications précédentes en une forme immobilisée.
20. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage médical.
21. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le traitement de la douleur.
22. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le traitement de la douleur chronique.
23. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le traitement de la douleur aiguë.
- 50 24. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le traitement de la douleur associée à l'un ou plusieurs des suivants: pancréatites, calculs rénaux, endométrioses, maladies inflammatoires chroniques intestinales (IBD), maladie de Crohn, adhérences post-chirurgicales, calculs biliaires, maux de tête, dysménorrhées, douleurs musculo-squelettiques, entorses, douleurs viscérales, kystes ovariens, prostatites, cystites, cystites interstitielles, douleurs post-opératoires, migraines, névralgies du trijumeau, douleurs issues de brûlures et/ou blessures, douleurs liées aux traumatismes, douleurs neuropathiques, douleurs liées aux troubles musculo-squelettiques, arthrites rhumatoïdes, ostéo-arthrites (arthroses), spondylarthrites ankylosantes, pathologies périarticulaires, douleurs oncologiques, douleurs issues de métastases osseuses, infections VIH.
- 55

25. Un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le traitement du cancer, d'un trouble neuronal (p.ex. affection neuro-dégénérative), de la maladie d'Alzheimer, du diabète sucré, d'un trouble viral, de troubles médiés par VIH, de la lèpre ou d'une maladie inflammatoire.
- 5 26. Un anticorps ou dérivé à usage selon l'une quelconque des revendications 21 à 25, dans lequel le traitement met enjeu la cytotoxicité cellulaire dépendant des anticorps (ADCC).
27. Une combinaison d'un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19 et d'un analgésique, pour une administration simultanée, séquentielle ou concertée en médecine.
- 10 28. Une combinaison d'un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19 et d'un facteur de croissance du tissu nerveux (NGF), pour une administration simultanée, séquentielle ou concertée en médecine.
29. Une combinaison d'un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19 et d'un autre anticorps anti-TrkA ou dérivé de celui-ci, pour une administration simultanée, séquentielle ou concertée en médecine.
- 15 30. Une composition pharmaceutique comprenant un anticorps ou son dérivé selon l'une quelconque des revendications 1 à 19 et d'un véhicule ou excipient pharmaceutiquement acceptable.
31. Une composition pharmaceutique comprenant un anticorps selon l'une quelconque des revendications 1 à 19 et un autre agent actif pharmaceutiquement.
- 20 32. Une composition pharmaceutique selon la revendication 31, dans laquelle ledit autre agent est un ou plusieurs parmi:
- 25 a) un agent analgésique
b) un autre anticorps anti-TrkA ou son dérivé
c) un facteur de croissance du tissu nerveux (NGF)
d) un agent anti-cancer.
- 30 33. Un anticorps ou son dérivé selon l'une quelconque des revendications 1 à 19, à usage dans le diagnostic ou le pronostic.
34. Un anticorps ou son dérivé à usage dans le diagnostic ou le pronostic de l'une quelconque des maladies ou de l'un quelconque des troubles spécifiés dans les revendications 21 à 25.
- 35 35. Un acide nucléique codant un anticorps ou son dérivé selon l'une quelconque des revendications 1 à 19.
36. Un vecteur comprenant un acide nucléique selon la revendication 35.
- 40 37. Un mammifère transgénique non-humain exprimant un anticorps ou son dérivé selon l'une quelconque des revendications 1 à 19 ou qui peut être induit à fournir une telle expression.
38. Un kit d'éléments comprenant un anticorps ou dérivé selon l'une quelconque des revendications 1 à 19, avec des instructions prescrivant son utilisation par un patient comme analgésique.
- 45
- 50
- 55

Figure 1a

Sequence Alignment

Underlined, CDRs, as of EP1181318

HEAVY CHAIN:

mVHEP
 EVKLMEGGGLVQPGGSLRLSCAASGFTSTYMSWARQTPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMSSLSKSDTALYYCARGAMYGNDFFYPMDYWGQGTSITVTVSS
 (SEQ IN No. 15)
 3-23*01
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTSYANSWVRQAPGKLEWVAISGSGSTYYADSVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCAK.....
 (SEQ IN No. 19)
 JH4
YFDYWGQGLTVTVSS
 (SEQ IN No. 20)
 BZhVH1
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTYMSWVRQAPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCARGAMYGNDFFYPMDYWGQGTITVTVSS
 (SEQ IN No. 1)
 BZhVH2
 EVKLLESGGGLVQPGGSLRLSCAASGFTSTYMSWVRQTPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCARGAMYGNDFFYPMDYWGQGTITVTVSS
 (SEQ IN No. 2)
 BZhVH3
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTYMSWVRQTPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCARGAMYGNDFFYPMDYWGQGTITVTVSS
 (SEQ IN No. 3)
 BZhVH4
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTYMSWVRQAPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCARGAMYGNDFFYPMDYWGQGTITVTVSS
 (SEQ IN No. 4)
 BZhVH5
 EVKLLESGGGLVQPGGSLRLSCAASGFTSTYMSWVRQTPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDTAVYYCARGAMYGNDFFYPMDYWGQGTITVTVSS
 (SEQ IN No. 5)
 HvVHMO
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTYMSWARQAPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDSAVYYCARGAMYGNDFFYPMDRWGQGLTVTVSS
 (SEQ IN No. 17)
 HvVHMOv
 EVQLLESGGGLVQPGGSLRLSCAASGFTSTYMSWARQAPGKLEWVAISKGGSTYYPDTVKGRFTISRDNKNTLYLQMISLRAEDSAVYYCARGAMYGNDFFYPMDYWGQGLTVTVSS
 (SEQ IN No. 6)

Figure 1b

LIGHT CHAIN:

mVLEP
 DIVLTQSPAIMSALGEEITLTCASSSSVSYMH-WYQOKSGTSPKLLIYTTSNLASGVPSRFGSGSGTFFYSLTSSVEADAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 16)
 L6*01
 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQOKPGQAPRLIYDASNRAIGIPARFSGSGTDFTLTSSLEPEDFAVYYCQQRSNWP.....
 (SEQ IN No. 21)
 JK1
WTFGGGCKVEIK
 (SEQ IN No. 22)
 BxhVL1
 EIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQAPRLIYTTSNLASGIPARFSGSGTDFTLTSSLEPEDFAVYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 7)
 BxhVL2
 EIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTDFTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 8)
 BxhVL3
 QIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTFFYTLTSSLEPEDFAVYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 9)
 BxhVL4
 QIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTDFTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 10)
 BxhVL5
 QIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTDFTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 11)
 BxhVL6
 EIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTFFYTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 12)
 BxhVL7
 QIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKPGQSPRLIYTTSNLASGIPSRFSGSGTFFYTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 13)
 BxhVL8
 QIVLTQSPATLSLSPGERATLSCASSSSVSYMH-WYQOKSGTSPRLIYTTSNLASGIPSRFSGSGTFFYTLTSSLEPEDAADYYCHQWSSYPWTFGGGCKLEIK
 (SEQ IN No. 14)
 HuVLMO
 DIVLTQSPSSLSASVGDRTITCSASSSVSYMH-WYQOKPGQAPKLLIYTTSNLASGVPSRFGSGSGTDYTLTSSLPEDVATYYCHQWSSYPWTFGGGCKVEIK
 (SEQ IN No. 18)

Figure 2




Figure 2 (continued)




Figure 3




Figure 3 (continued)




Figure 4

TF1 Binding






Figure 4 (continued)



BXhVH3VL3

Figure 4 (continued)


TF1 Binding – Exp 1



BXhVH5VL1

Figure 4 (continued)


TF1 Binding – Exp 1



BXhVH5VL3

Figure 4 (continued)

TF1 Binding – Exp 1



HuMNACWOV

Figure 4 (continued)

TF1 Binding – Exp II






Figure 4 (continued)



BXhVH5VL1

Figure 4 (continued)


TF1 Binding – Exp II




BXhVH5VL3

Figure 4 (continued)

TF1 Binding – Exp II



HUMNACWOV






Figure 5 (continued)

Figure 5 (continued)

TF1 Proliferation Test




Figure 5 (continued)

TF1 Proliferation Test




Figure 5 (continued)

TF1 Proliferation Test




Figure 5 (continued)




Figure 5 (continued)




Figure 6

BXhVH5 heavy chain with constant region

EVKLLSEGGGLVQPGGSLRLSCAASGFTFSTY^{MS}WVRQTPGK
 RLEWAYISKGGSTYYPDTVKGRFTISRDNSKNTLYLQMNSLRA
 EDTAVYYCARGAMYGNDFFYPMDYWGGQT^{TV}SSASTKGPSV
 FPLAPSSKSTSGGTAALGCLVKDYFPEPVT^{SV}WNSGALTSGVHTF
 PAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
 EPKSCDKTHTCPPCPAPELGGPSVFLFPPKPKDTLMISRTPEVT
 CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
 SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
 TPPVLDSDGSFFLYSKLTVDKSRWQQGNV^FSCSVMH^EGLHNHYT
 QKSLSLSPGK

BXhVL1 light chain with constant region

EIVLTQSPATLSLSPGERATLSCSASSSV^{SY}MHWYQQKPGQAPRL
 LIYTTSNLASGIPARFSGSGTDFTLTISSELEPEDFAVYYCHQWS
 SYPWTFGQGTKLEIK^{RT}VAAPSVFIFPPSDEQLKSGTASV^VCLLN
 NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS^TSYLSSTLT
 LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Figure 7

BXhVH5 N297A heavy chain with constant region

EVKLLESGGGLVQPGGSLRLSCAASGFTFTSTYTM^{SV}VRQTPGKRLEWVAYISKGGGSTYYPD^{TV}
 KGRFTISRDN^{SK}NTLYLQMN^{SL}RAEDTA^{VYYC}ARGAM^{YGN}DFEY^{PM}DYWGQ^{GT}TVT^{VSSA}STKG
 PSVFP^{LAP}SSKSTSGGTAALGCLVKDYFPEP^{VT}SV^{SN}SGALTSGVHTFPAVLQSSGLYSLSSV^V
 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
 LMSRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLT^VLHQDWL
 NGKEYKCKVSNKALPAPIEK^{TI}SKAKGQPREPQ^{VY}TLPPSRDELTKNQVSLTCLVKGFYPSDIA
 VEWESNGQPENNYK^{TT}PPVLDSDGSFFLYSKLTVDKSRWQQGNV^{FS}CSVMHEGLHNHYTQKSLS
 LSPGK

Figure 8

TF1





Figure 8 (continued)



HuMNACWON297A

Figure 8 (continued)





Figure 8 (continued)

TF1



BXhVH5VL1N297A

Figure 8 (continued)

HMC1





Figure 8 (continued)


HMC1



HuMNAcWON297A

Figure 8 (continued)


HMC1



BXhVH5VL1

Figure 8 (continued)

HMC1



BXhVH5VL1N297A

Figure 8 (continued)





Figure 8 (continued)



HuMNACWON297A

Figure 8 (continued)





Figure 8 (continued)

PC12-huTrkA



BXhVH5VL1N297A

Figure 9




Figure 10





Figure 11

Figure 12





Figure 13




Figure 13 (continued)




Figure 13 (continued)




Figure 13 (continued)




Figure 13 (continued)




Figure 14




Figure 14 (continued)






Figure 14 (continued)



* p<0.05 paired T test vs right paw
 ** p<0.01 paired T test vs right paw

Figure 14 (continued)



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9721732 A [0005] [0008]
- WO 0073344 A [0006] [0007] [0011] [0042] [0065] [0068]
- EP 118138 B [0006]
- WO 06131952 A [0009] [0065] [0093]
- WO 06137106 A [0010] [0069] [0082]
- WO 05061540 A [0011] [0012] [0013] [0024] [0065] [0190]
- WO 06131592 A [0070] [0102]
- US 6194551 B [0136] [0170]
- US 6491916 B [0137] [0170]
- US 5624821 A [0138] [0170] [0273]
- WO 9845435 A [0177]
- WO 9108216 A [0181]
- EP 1181318 A [0189]

Non-patent literature cited in the description

- **KABAT.** Sequences of Proteins of Immunological Interest. National Institutes of Health, 1987 [0024]
- **CHOTHIA ; LESK.** *J. Mol. Biol.*, 1987, vol. 196, 901 [0024]
- **CHOTHIA et al.** *Nature*, 1989, vol. 342, 878 [0024]
- **MCMAHON et al.** *Nature Medicine*, 1995, vol. 1, 774-780 [0068]
- **EDDY ; LEIMBACH.** *J. Phar. Exp. Ther.*, 1953, vol. 107, 385-393 [0068]
- **PORRO ; CAVAZZUTI.** *Prog. Neurobiol.*, 1993, vol. 41, 565-607 [0069]
- **BENNETT ; XIE.** *Pain*, 1988, vol. 33, 87-107 [0070]
- **WARD ; GHETIE.** *Therapeutic Immunology*, 1995, vol. 2, 77-94 [0136]
- **HUSTON et al.** *PNAS*, 1988, vol. 85, 5879 [0147]
- **BIRD et al.** *Science*, 1988, vol. 242, 423 [0147]
- **BUCHNER ; RUDOLPH.** *Biol/Technology*, 1991, vol. 9, 157 [0147]
- **SKERRA et al.** *Biol/Technology*, 1991, vol. 9, 273 [0147]
- **HOLLIGER ; HUDSON.** *Nature Biotechnology*, 1995, vol. 23 (9), 1126-1136 [0148]
- **THORPE et al.** *Monoclonal Antibodies in Clinical Medicine*. Academic Press, 168 [0155]
- **CHEN et al.** *Gene Ther.*, 1995, vol. 2, 116 [0158]
- **CESARENI.** *FEBS Letts*, 1992, vol. 307, 66 [0166]
- **SWIMMER et al.** *PNAS*, 1992, vol. 89, 3756 [0166]
- **GRAM et al.** *PNAS*, 1992, vol. 89, 3576 [0166]
- **CLACKSON et al.** *Nature*, 1991, vol. 352, 624 [0166]
- **SCOTT ; SMITH.** *Science*, 1990, vol. 249, 386 [0166]
- **GARRARD et al.** *Biol/Techniques*, 1991, vol. 9, 1373 [0166]
- **PUTLITZ et al.** *Biol/Technology*, 1990, vol. 8, 651 [0167]
- **LARRICK ; FRY.** *Hum. Antibodies Hybridomas*, 1991, vol. 2, 172 [0168]
- **BENVENUTO et al.** *Plant Mol. Biol.*, 1991, vol. 17, 865 [0168]
- **DURIN et al.** *Plant Mol. Biol.*, 1990, vol. 15, 281 [0168]
- **HIATT et al.** *Nature*, 1989, vol. 342, 76 [0168]
- **WINNACKER.** *From Genes to Clones*. VCH Publishers, 1987 [0169]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323 [0169]
- **QUEEN et al.** *PNAS*, 1989, vol. 86, 10029 [0171]
- **JONES ; DEAR ; FOOTE ; NEUBERGER ; WINTER.** *Nature*, 1986, vol. 321, 522-4 [0174]
- **RIECHMANN ; CLARK ; WALDMAN ; WINTER.** *Nature*, 1988, vol. 332, 323-327 [0174]
- **VERHOEYEN ; MILSTEIN ; WINTER.** *Science*, 1988, vol. 239, 1534-1536 [0174]
- **BUHLER et al.** *Biol/Technology*, 1990, vol. 8, 140 [0180]
- **MEADE et al.** *Biol/Technology*, 1990, vol. 8, 443 [0180]
- **KITAMURA, T. et al.** *J. Cell Physiol.*, 1989, vol. 140, 323-334 [0238]
- **AHAMED, J. et al.** *J Immunol.*, 01 June 2004, vol. 172 (11), 6961-8 [0262]